cdc
infecti
diseas
societi
america
american
societi
blood
marrow
transplant
cosponsor
guidelin
prevent
opportunist
infect
oi
among
hematopoiet
stem
cell
transplant
hsct
recipi
guidelin
draft
assist
work
group
expert
infecti
diseas
transplant
public
health
purpos
report
hsct
defin
transplant
bloodor
marrowderiv
hematopoiet
stem
cell
regardless
transplant
type
ie
allogen
autolog
cell
sourc
ie
bone
marrow
peripher
blood
placent
umbil
cord
blood
oi
bacteri
viral
fungal
protozo
helminth
infect
occur
increas
frequenc
sever
among
hsct
recipi
evidencebas
guidelin
contain
inform
regard
prevent
oi
hospit
infect
control
strategi
safe
live
transplant
vaccin
hematopoiet
stem
cell
safeti
diseasespecif
section
address
prevent
exposur
diseas
pediatr
adult
autolog
allogen
hsct
recipi
goal
guidelin
twofold
summar
current
data
provid
evidencebas
recommend
regard
prevent
oi
among
hsct
patient
guidelin
develop
use
hsct
recipi
household
close
contact
transplant
infecti
diseas
physician
hsct
center
personnel
public
health
profession
recommend
prevent
strategi
rate
strength
recommend
qualiti
evid
support
recommend
adher
guidelin
reduc
number
sever
oi
among
hsct
recipi
institut
medicin
recommend
cdc
lead
global
effort
detect
control
emerg
infecti
agent
respons
cdc
publish
plan
outlin
nation
diseas
prevent
prioriti
includ
develop
guidelin
prevent
opportunist
infect
oi
among
immunosuppress
person
cdc
publish
guidelin
prevent
oi
among
person
infect
human
immunodefici
viru
hiv
revis
guidelin
success
guidelin
cdc
sought
determin
need
expand
oi
prevent
activ
immunosuppress
popul
inform
survey
hematolog
oncolog
infecti
diseas
specialist
transplant
center
work
group
form
cdc
determin
guidelin
need
help
prevent
oi
among
hematopoiet
stem
cell
transplant
hsct
recipi
work
group
defin
oi
infect
occur
increas
frequenc
sever
among
hsct
recipi
draft
evidencebas
recommend
prevent
exposur
diseas
caus
bacteri
fungal
viral
protozo
helminth
pathogen
march
work
group
present
first
draft
guidelin
meet
repres
public
privat
health
organ
review
group
expert
guidelin
revis
made
avail
septemb
public
comment
period
notif
feder
regist
public
comment
ad
feasibl
report
approv
cdc
infecti
diseas
societi
america
american
societi
blood
marrow
transplant
pediatr
content
guidelin
endors
also
american
academi
pediatr
hematopoiet
stem
cell
safeti
section
endors
intern
societi
hematotherapi
graft
engin
first
recommend
present
report
follow
recommend
hospit
infect
control
strategi
safe
live
vaccin
hematopoiet
stem
cell
safeti
unless
otherwis
note
recommend
address
allogen
autolog
pediatr
adult
hsct
recipi
addit
recommend
intend
use
recipi
household
close
contact
transplant
infecti
diseas
specialist
hsct
center
personnel
public
health
profession
report
hsct
defin
transplant
bloodor
marrowderiv
hematopoiet
stem
cell
regardless
transplant
type
eg
allogen
autolog
cell
sourc
eg
bone
marrow
peripher
blood
placentalumbil
cord
blood
addit
hsct
recipi
presum
immunocompet
month
hsct
immunosuppress
therapi
graftversushost
diseas
gvhd
condit
occur
transplant
cell
recogn
recipi
cell
cell
attack
recommend
prevent
strategi
rate
strength
recommend
tabl
qualiti
evid
tabl
support
recommend
principl
rate
system
develop
infecti
diseas
societi
america
us
public
health
servic
use
guidelin
prevent
oi
among
hivinfect
person
rate
system
allow
assess
recommend
adher
critic
hsct
infus
hematopoiet
stem
cell
donor
patient
receiv
chemotherapi
usual
marrowabl
increasingli
hsct
use
treat
neoplast
diseas
hematolog
disord
immunodefici
syndrom
congenit
enzym
defici
autoimmun
disord
eg
system
lupu
erythematosu
multipl
sclerosi
moreov
hsct
becom
standard
treatment
select
condit
data
hsct
classifi
either
allogen
autolog
basi
sourc
transplant
hematopoiet
progenitor
cell
cell
use
allogen
hsct
harvest
donor
transplant
recipi
transplant
effect
treatment
person
sever
aplast
anemia
offer
cur
therapi
person
chronic
myelogen
leukemia
allogen
donor
might
blood
rel
unrel
donor
allogen
transplant
usual
success
donor
human
lymphocyt
antigen
hla
ident
twin
match
sibl
howev
allogen
candid
lack
donor
registri
organ
eg
nation
marrow
donor
program
maintain
computer
databas
store
inform
regard
hla
type
million
volunt
donor
anoth
sourc
stem
cell
allogen
candid
without
hlamatch
sibl
mismatch
famili
member
howev
person
receiv
allogen
graft
donor
hlamatch
sibl
substanti
greater
risk
graftversushost
diseas
gvhd
person
also
increas
risk
suboptim
graft
function
delay
immun
system
recoveri
reduc
gvhd
among
allogen
hsct
techniqu
develop
remov
tlymphocyt
princip
effector
gvhd
donor
graft
although
recipi
tlymphocytedeplet
marrow
graft
gener
lower
rate
gvhd
also
greater
rate
graft
reject
cytomegaloviru
cmv
infect
invas
fungal
infect
epsteinbarr
viru
ebv
associ
posttranspl
lymphoprolif
diseas
patient
cell
use
autolog
hsct
similar
autolog
transplant
syngen
transplant
among
hlaident
twin
serv
donor
autolog
hsct
prefer
patient
requir
highlevel
marrowabl
chemotherapi
erad
underli
malign
healthi
undiseas
bone
marrow
autolog
hsct
also
prefer
immunolog
antitumor
effect
allograft
benefici
autolog
hsct
use
frequent
treat
breast
cancer
nonhodgkin
lymphoma
hodgkin
diseas
neither
autolog
syngen
hsct
confer
risk
chronic
gvhd
recent
medic
center
begun
harvest
hematopoiet
stem
cell
placent
umbil
cord
blood
ucb
immedi
birth
harvest
cell
use
primarili
allogen
transplant
among
children
earli
result
demonstr
greater
degre
histoincompat
donor
recipi
might
toler
without
graft
reject
gvhd
ucb
hematopoiet
cell
use
howev
immun
system
function
ucb
transplant
wellstudi
hsct
also
evolv
rapidli
area
exampl
hematopoiet
stem
cell
harvest
patient
peripher
blood
treatment
hematopoiet
colonystimul
factor
eg
granulocyt
colonystimul
factor
gcsf
filgastrim
granulocytemacrophag
colonystimul
factor
gmcsf
sargramostim
use
increasingli
among
autolog
recipi
investig
use
among
allogen
hsct
peripher
blood
larg
replac
bone
marrow
sourc
stem
cell
autolog
recipi
benefit
harvest
cell
donor
peripher
blood
instead
bone
marrow
elimin
need
gener
anesthesia
associ
bone
marrow
aspir
gvhd
condit
donat
cell
recogn
recipi
cell
nonself
attack
although
use
intraven
immunoglobulin
ivig
routin
manag
allogen
patient
common
past
mean
produc
immun
modul
among
patient
gvhd
practic
declin
cost
factor
develop
strategi
gvhd
prophylaxi
exampl
use
cyclosporin
gvhd
prophylaxi
becom
commonplac
sinc
introduct
earli
frequent
cyclosporin
tacrolimu
administ
combin
immunosuppress
agent
eg
methotrex
corticosteroid
although
cyclosporin
effect
prevent
gvhd
use
entail
greater
hazard
infecti
complic
relaps
underli
neoplast
diseas
transplant
perform
although
surviv
rate
certain
autolog
recipi
improv
infect
remain
lead
caus
death
among
allogen
transplant
major
caus
morbid
among
autolog
hsct
research
nation
marrow
donor
program
report
person
receiv
unrel
allogen
hsct
decemb
total
die
among
primari
secondari
caus
death
common
caus
infect
occur
among
patient
despit
high
morbid
mortal
hsct
recipi
surviv
longterm
like
enjoy
good
health
survey
person
receiv
hsct
surviv
year
hsct
determin
good
health
return
work
school
full
time
anoth
survey
adult
surviv
mean
year
hsct
respond
benefit
transplant
outweigh
side
effect
first
year
hsct
recipi
typic
follow
predict
pattern
immun
system
defici
recoveri
begin
chemotherapi
radiat
therapi
ie
condit
regimen
administ
hsct
treat
underli
diseas
unfortun
condit
regimen
also
destroy
normal
hematopoiesi
neutrophil
monocyt
macrophag
damag
mucos
progenitor
cell
caus
temporari
loss
mucos
barrier
integr
gastrointestin
tract
normal
contain
bacteria
commens
fungi
bacteriacarri
sourc
eg
skin
mucosa
becom
reservoir
potenti
pathogen
virtual
hsct
recipi
rapidli
lose
tand
blymphocyt
condit
lose
immun
memori
accumul
lifetim
exposur
infecti
agent
environment
antigen
vaccin
transfer
donor
immun
hsct
recipi
variabl
influenc
time
antigen
exposur
among
donor
recipi
passiv
acquir
donor
immun
reli
upon
provid
longterm
immun
infecti
diseas
among
hsct
recipi
first
month
hsct
major
hostdefens
deficit
includ
impair
phagocytosi
damag
mucocutan
barrier
addit
indwel
intraven
cathet
frequent
place
left
situ
week
administ
parenter
medic
blood
product
nutrit
supplement
cathet
serv
anoth
portal
entri
opportunist
pathogen
organ
colon
skin
eg
coagulaseneg
staphylococci
staphylococcu
aureu
candida
speci
enterococci
engraft
adult
children
defin
point
patient
maintain
sustain
absolut
neutrophil
count
anc
sustain
platelet
count
last
consecut
day
without
transfus
among
unrel
allogen
recipi
engraft
occur
median
day
hsct
rang
day
absenc
corticosteroid
use
engraft
associ
restor
effect
phagocyt
function
result
decreas
risk
bacteri
fungal
infect
howev
hsct
recipi
particularli
allogen
recipi
experi
immun
system
dysfunct
month
engraft
exampl
although
allogen
recipi
might
normal
total
lymphocyt
count
within
month
hsct
abnorm
tcell
ratio
reflect
decreas
increas
tcell
count
might
also
immunoglobulin
g
igg
igg
immunoglobulin
iga
defici
month
hsct
difficulti
switch
immunoglobulin
igm
igg
product
antigen
exposur
immun
system
recoveri
might
delay
cmv
infect
first
month
hsct
recipi
might
experi
acut
gvhd
manifest
skin
gastrointestin
liver
injuri
grade
scale
iiv
although
autolog
syngen
recipi
might
occasion
experi
mild
selflimit
ill
acut
gvhdlike
gvhd
occur
primarili
among
allogen
recipi
particularli
receiv
match
unrel
donor
transplant
gvhd
substanti
risk
factor
infect
among
hsct
recipi
associ
delay
immunolog
recoveri
prolong
immunodefici
addit
immunosuppress
agent
use
gvhd
prophylaxi
treatment
might
make
hsct
recipi
vulner
opportunist
viral
fungal
pathogen
certain
patient
particularli
adult
allogen
recipi
might
also
experi
chronic
gvhd
grade
either
limit
extens
chronic
gvhd
chronic
gvhd
appear
similar
autoimmun
connectivetissu
disord
eg
scleroderma
system
lupu
erythematosu
associ
cellular
humor
immunodefici
includ
macrophag
defici
impair
neutrophil
chemotaxi
poor
respons
vaccin
sever
mucos
risk
factor
chronic
gvhd
includ
increas
age
allogen
hsct
particularli
among
donor
unrel
nonhla
ident
famili
member
histori
acut
gvhd
chronic
gvhd
first
describ
occur
day
hsct
occur
day
hsct
although
allogen
recipi
chronic
gvhd
normal
high
total
serum
immunoglobulin
level
experi
longlast
iga
igg
igg
subclass
defici
poor
opson
impair
reticuloendotheli
function
consequ
even
greater
risk
infect
particularli
lifethreaten
bacteri
infect
encapsul
organ
eg
stre
pneumonia
ha
influenza
ne
meningitidi
chronic
gvhd
resolv
might
take
year
cellmedi
humor
immun
function
gradual
restor
hsct
recipi
experi
certain
infect
differ
time
posttranspl
reflect
predomin
hostdefens
defect
figur
immun
system
recoveri
hsct
recipi
take
place
three
phase
begin
day
day
transplant
phase
preengraft
phase
day
hsct
phase
ii
postengraft
phase
day
hsct
phase
iii
late
phase
day
hsct
prevent
strategi
base
three
phase
follow
inform
present
updat
data
publish
phase
preengraft
first
month
posttranspl
hsct
recipi
two
critic
risk
factor
infect
prolong
neutropenia
break
mucocutan
barrier
result
hsct
prepar
regimen
frequent
vascular
access
requir
patient
care
consequ
oral
gastrointestin
skin
flora
sourc
infect
preval
pathogen
includ
candida
speci
neutropenia
continu
aspergillu
speci
addit
herp
simplex
viru
hsv
reactiv
occur
phase
preengraft
risk
infect
autolog
allogen
patient
oi
appear
febril
neutropenia
although
recipi
first
fever
preengraft
probabl
caus
bacteri
pathogen
rare
organ
site
infect
identifi
instead
infect
usual
treat
preemptiv
empir
neutropenia
resolv
growth
factor
administ
phase
decreas
neutropenia
durat
complic
eg
febril
neutropenia
phase
ii
postengraft
phase
ii
domin
impair
cellmedi
immun
allogen
autolog
recipi
scope
impact
defect
allogen
recipi
determin
extent
gvhd
immunosuppress
therapi
engraft
herp
virus
particularli
cmv
critic
pathogen
day
hsct
cmv
caus
pneumonia
hepat
coliti
potenti
superinfect
opportunist
pathogen
particularli
among
patient
activ
gvhd
domin
pathogen
phase
includ
pneumocysti
carinii
aspergillu
speci
phase
iii
late
phase
phase
iii
autolog
recipi
usual
rapid
recoveri
immun
system
function
therefor
lower
risk
oi
allogen
recipi
cellmedi
humor
immun
defect
impair
reticuloendotheli
system
function
allogen
patient
chronic
gvhd
recipi
altern
donor
allogen
transplant
risk
certain
infect
phase
altern
donor
includ
match
unrel
ucb
mismatch
familyrel
donor
patient
risk
infect
includ
cmv
varicellazost
viru
vzv
ebvrel
posttranspl
lymphoprolif
diseas
communityacquir
respiratori
virus
crv
infect
encapsul
bacteria
eg
ha
influenza
stre
pneumonia
risk
infect
approxim
proport
sever
patient
gvhd
phase
ii
iii
patient
receiv
mismatch
allogen
transplant
higher
attack
rate
sever
gvhd
therefor
higher
risk
oi
phase
ii
iii
patient
receiv
match
allogen
hsct
contrast
patient
undergo
autolog
transplant
primarili
risk
infect
phase
prevent
infect
among
hsct
recipi
prefer
treat
infect
howev
despit
recent
technolog
advanc
research
need
optim
health
outcom
hsct
recipi
effort
improv
immun
system
reconstitut
particularli
among
allogen
transplant
recipi
prevent
resolv
immun
dysregul
result
donorrecipi
histoincompat
gvhd
remain
substanti
challeng
prevent
recurr
persist
progress
infect
among
hsct
patient
suscept
profil
particularli
use
singl
antibiot
antibacteri
prophylaxi
biii
emerg
fluoquinoloneresist
coagulaseneg
staphylococci
es
coli
vancomycinintermedi
sta
aureu
vancomycinresist
enterococcu
vre
increas
concern
vancomycin
use
agent
routin
bacteri
prophylaxi
diii
growth
factor
eg
gmcsf
gcsf
shorten
durat
neutropenia
hsct
howev
data
found
indic
whether
growth
factor
effect
reduc
attack
rate
invas
bacteri
diseas
physician
routin
administ
ivig
product
hsct
recipi
bacteri
infect
prophylaxi
dii
although
ivig
recommend
use
produc
immun
system
modul
gvhd
prevent
research
recommend
routin
ivig
use
prevent
bacteri
infect
among
approxim
hsct
recipi
unrel
marrow
graft
experi
sever
hypogammaglobulinemia
eg
igg
mgdl
within
first
day
transplant
ciii
exampl
recipi
hypogammaglobulinem
might
receiv
prophylact
ivig
prevent
bacteri
sinopulmonari
infect
eg
stre
pneumonia
ciii
hypogammaglobulinem
allogen
recipi
physician
use
higher
frequent
dose
ivig
standard
nonhsct
recipi
ivig
halflif
among
hsct
recipi
gener
day
much
shorter
halflif
among
healthi
adult
gener
day
addit
infect
might
acceler
igg
catabol
therefor
ivig
dose
hypogammaglobulinem
recipi
individu
maintain
trough
serum
igg
concentr
mgdl
bii
consequ
physician
monitor
trough
serum
igg
concentr
among
patient
approxim
everi
week
adjust
ivig
dose
need
biii
appendix
prevent
late
diseas
day
hsct
antibiot
prophylaxi
recommend
prevent
infect
encapsul
organ
eg
stre
pneumonia
ha
influenza
ne
meningitidi
among
allogen
recipi
chronic
gvhd
long
activ
chronic
gvhd
treatment
administ
biii
antibiot
select
guid
local
antibiot
resist
pattern
absenc
sever
demonstr
hypogammaglobulinemia
eg
igg
level
mgdl
might
associ
recurr
sinopulmonari
infect
routin
monthli
ivig
administr
hsct
recipi
day
hsct
recommend
di
mean
prevent
bacteri
infect
diseas
prevent
recommend
routin
use
ivig
among
autolog
recipi
recommend
dii
recommend
prevent
bacteri
infect
among
pediatr
adult
hsct
recipi
appropri
care
precaut
taken
hospit
patient
infect
stre
pneumonia
biii
prevent
exposur
among
hsct
recipi
inform
regard
current
avail
pneumococc
polysaccharid
vaccin
indic
limit
immunogen
among
hsct
recipi
howev
potenti
benefit
certain
patient
administ
hsct
recipi
month
hsct
biii
data
found
regard
safeti
immunogen
conjug
pneumococc
vaccin
among
hsct
recipi
therefor
recommend
regard
use
vaccin
made
antibiot
prophylaxi
recommend
prevent
infect
encapsul
organ
eg
stre
pneumonia
ha
influenza
ne
meningitidi
among
allogen
recipi
chronic
gvhd
long
activ
chronic
gvhd
treatment
administ
biii
trimethoprimsulfamethasaxol
tmpsmz
administ
pneumocysti
carinii
pneumonia
pcp
prophylaxi
also
provid
protect
pneumococc
infect
howev
data
found
support
use
tmpsmz
prophylaxi
among
hsct
recipi
sole
purpos
prevent
stre
pneumonia
diseas
certain
strain
stre
pneumonia
resist
tmpsmz
penicillin
recommend
prevent
pneumococc
infect
allogen
autolog
recipi
adult
pediatr
hsct
recipi
age
year
administ
current
pneumococc
polysaccharid
vaccin
vaccin
effect
biii
howev
vaccin
administ
children
age
year
effect
among
age
popul
di
data
found
regard
safeti
immunogen
conjug
pneumococc
vaccin
among
pediatr
hsct
recipi
therefor
recommend
regard
use
vaccin
made
induct
cours
usual
start
engraft
ai
although
physician
add
brief
prophylact
cours
hsct
precondit
ciii
appendix
preemptiv
strategi
earli
cmv
ie
day
hsct
allogen
recipi
prefer
prophylaxi
cmvseroneg
hsct
recipi
seroposit
donor
cell
ie
dposit
rneg
low
attack
rate
activ
cmv
infect
screen
filter
blood
product
support
use
bii
preemptiv
strategi
restrict
ganciclovir
use
patient
evid
cmv
infect
hsct
requir
use
sensit
specif
laboratori
test
rapidli
diagnos
cmv
infect
hsct
enabl
immedi
administr
ganciclovir
cmv
infect
detect
allogen
recipi
risk
screen
timesweek
day
day
hsct
ie
phase
ii
presenc
cmv
viremia
antigenemia
aiii
hsct
physician
select
one
two
diagnost
test
determin
need
preemptiv
treatment
current
detect
cmv
antigen
leukocyt
antigenemia
prefer
screen
preemptiv
treatment
rapid
sensit
cultur
good
posit
predict
valu
direct
detect
cmvdna
deoxyribonucl
acid
polymeras
chain
reaction
pcr
sensit
low
posit
predict
valu
although
cmvdna
pcr
less
sensit
whole
blood
leukocyt
pcr
plasma
cmvdna
pcr
use
neutropenia
number
leukocytesslid
low
allow
cmv
antigenemia
test
viru
cultur
urin
saliva
blood
bronchoalveolar
wash
rapid
shellvial
cultur
routin
cultur
use
howev
viral
cultur
techniqu
less
sensit
cmvdna
pcr
cmv
antigenemia
test
also
rapid
shellvir
cultur
requir
hour
routin
viral
cultur
requir
week
obtain
final
result
thu
viral
cultur
techniqu
less
satisfactori
pcr
antigenemia
test
hsct
center
without
access
pcr
antigenemia
test
use
prophylaxi
rather
preemptiv
therapi
cmv
diseas
prevent
bii
physician
use
diagnost
test
eg
hybrid
captur
cmvdna
assay
version
cmv
viral
rna
ribonucl
acid
detect
howev
limit
data
found
regard
use
among
hsct
recipi
therefor
recommend
use
made
allogen
recipi
day
hsct
ie
phase
ii
begin
preemptiv
treatment
ganciclovir
cmv
viremia
antigenemia
detect
recipi
consecut
posit
cmvdna
pcr
test
biii
preemptiv
treatment
start
mainten
ganciclovir
usual
continu
day
hsct
minimum
week
whichev
longer
ai
appendix
antigen
pcr
test
neg
ganciclovir
stop
studi
report
shorter
cours
ganciclovir
eg
week
neg
pcr
antigenemia
occur
might
provid
adequ
cmv
prevent
less
toxic
routin
weekli
screen
antigen
pcr
test
necessari
stop
ganciclovir
cmv
reactiv
occur
biii
present
intraven
formul
ganciclovir
approv
use
cmv
prophylact
preemptiv
strategi
biii
recommend
oral
ganciclovir
use
among
hsct
recipi
made
clinic
trial
evalu
efficaci
still
progress
one
group
use
ganciclovir
foscarnet
altern
day
cmv
prevent
recommend
made
regard
strategi
limit
data
patient
ganciclovirintoler
administ
foscarnet
instead
bii
appendix
hsct
recipi
receiv
ganciclovir
anc
check
timesweek
biii
research
report
manag
ganciclovirassoci
neutropenia
ad
gcsf
temporarili
stop
ganciclovir
day
patient
anc
ciii
ganciclovir
restart
patient
anc
consecut
day
altern
research
report
substitut
foscarnet
ganciclovir
hsct
recipi
still
cmv
virem
antigenem
b
anc
remain
day
ganciclovir
stop
ciii
appendix
neutropenia
accompani
ganciclovir
administr
usual
brief
patient
requir
antifung
antibacteri
prophylaxi
diii
current
benefit
report
routin
administ
ganciclovir
prophylaxi
hsct
recipi
day
hsct
ie
phase
iii
howev
person
high
risk
late
cmv
diseas
routin
screen
biweekli
evid
cmv
reactiv
long
substanti
immunocompromis
persist
biii
risk
factor
late
cmv
diseas
includ
allogen
hsct
accompani
chronic
gvhd
steroid
use
low
count
delay
high
avid
anticmv
antibodi
recipi
match
unrel
tcelldeplet
hsct
high
risk
cmv
still
detect
routin
screen
day
hsct
ganciclovir
continu
cmv
longer
detect
ai
lowgrad
cmv
antigenemia
posit
cellsslid
detect
routin
screen
antigenemia
test
repeat
day
biii
cmv
antigenemia
indic
cellsslid
pcr
posit
shellvial
cultur
detect
cmv
viremia
cours
preemptiv
ganciclovir
treatment
administ
biii
appendix
ganciclovir
also
start
patient
consecut
posit
viremia
pcr
test
eg
person
receiv
steroid
gvhd
receiv
ganciclovir
foscarnet
day
hsct
current
investig
strategi
prevent
late
cmv
diseas
includ
use
target
prophylaxi
antivir
drug
cellular
immunotherapi
defici
absent
cmvspecif
immun
system
function
viremia
persist
week
ganciclovir
preemptiv
therapi
level
antigenemia
continu
rise
week
therapi
ganciclovirresist
cmv
suspect
cmv
viremia
recur
continu
treatment
ganciclovir
research
report
restart
ganciclovir
induct
stop
ganciclovir
start
foscarnet
ciii
limit
data
found
regard
use
foscarnet
among
hsct
recipi
either
cmv
prophylaxi
preemptiv
therapi
infus
donorderiv
cmvspecif
clone
tcell
transplant
recipi
evalu
fda
investig
new
drug
author
therefor
recommend
made
although
substanti
cooper
studi
highdos
acyclovir
certain
efficaci
prevent
cmv
diseas
util
limit
set
potent
anticmv
agent
eg
ganciclovir
use
acyclovir
effect
prevent
cmv
diseas
autolog
hsct
therefor
recommend
cmv
preemptiv
therapi
dii
consequ
valacyclovir
although
studi
use
among
hsct
recipi
presum
less
effect
ganciclovir
cmv
current
recommend
cmv
diseas
prevent
dii
although
hsct
physician
continu
use
ivig
immun
system
modul
ivig
recommend
cmv
diseas
prophylaxi
among
hsct
recipi
di
cidofovir
nucleosid
analog
approv
fda
treatment
aidsassoci
cmv
retin
drug
major
disadvantag
nephrotox
cidofovir
current
fda
phase
trial
use
among
hsct
recipi
therefor
recommend
use
made
use
cmvneg
leukocytereduc
blood
product
routin
requir
autolog
recipi
substanti
lower
risk
cmv
diseas
howev
cmvneg
leukocytereduc
blood
product
use
cmvseroneg
autolog
recipi
ciii
research
report
cmv
seroposit
autolog
recipi
evalu
preemptiv
therapi
underli
hematolog
malign
eg
lymphoma
leukemia
receiv
intens
condit
regimen
graft
manipul
recent
receiv
fludarabin
cda
ciii
subpopul
autolog
recipi
monitor
weekli
time
engraft
day
hsct
cmv
reactiv
prefer
quantit
cmv
antigen
quantit
pcr
bii
autolog
recipi
high
risk
experi
cmv
antigenemia
ie
blood
level
posit
cellsslid
receiv
week
preemptiv
treatment
ganciclovir
foscarnet
patient
treat
level
antigenemia
bii
appendix
prophylact
approach
cmv
diseas
prevent
appropri
cmvseroposit
autolog
recipi
indic
use
cmv
prophylaxi
preemptiv
treatment
children
adult
transplant
candid
particularli
ebvseroneg
advis
behavior
could
decreas
likelihood
ebv
exposur
aii
exampl
hsct
recipi
candid
follow
safe
hygien
practic
eg
frequent
hand
wash
aiii
avoid
share
cup
glass
eat
utensil
other
biii
avoid
contact
potenti
infect
respiratori
secret
saliva
aii
infus
donorderiv
ebvspecif
cytotox
tlymphocyt
demonstr
promis
prophylaxi
ebvlymphoma
among
recipi
tcelldeplet
unrel
mismatch
allogen
recipi
howev
insuffici
data
found
recommend
use
prophylaxi
preemptiv
therapi
acyclovir
recommend
lack
efficaci
dii
hsct
candid
test
serum
antihsv
igg
transplant
aiii
howev
typespecif
antihsv
igg
serolog
test
necessari
fdalicens
approv
test
use
hsct
candid
particularli
hsvseroneg
inform
import
avoid
hsv
infect
immunocompromis
advis
behavior
decreas
likelihood
hsv
exposur
aii
hsct
recipi
candid
avoid
share
cup
glass
eat
utensil
other
biii
sexual
activ
patient
longterm
monogam
relationship
alway
use
latex
condom
sexual
contact
reduc
risk
exposur
hsv
well
sexual
transmit
pathogen
aii
howev
even
longtim
monogam
pair
discord
hsv
infect
therefor
period
immunocompromis
sexual
activ
hsct
recipi
relationship
ask
partner
test
serum
hsv
igg
antibodi
partner
discord
consid
use
latex
condom
sexual
contact
reduc
risk
exposur
sexual
transmit
oi
ciii
person
dissemin
primari
sever
mucocutan
hsv
diseas
place
contact
precaut
durat
ill
ai
prevent
transmiss
hsv
hsct
recipi
acyclovir
acyclovir
prophylaxi
offer
hsvseroposit
allogen
recipi
prevent
hsv
reactiv
earli
posttranspl
period
ai
standard
approach
begin
acyclovir
prophylaxi
start
condit
therapi
continu
engraft
occur
mucos
resolv
whichev
longer
approxim
day
hsct
biii
appendix
without
support
data
control
studi
routin
use
antivir
prophylaxi
day
hsct
prevent
hsv
recommend
diii
routin
acyclovir
prophylaxi
indic
hsvseroneg
hsct
recipi
even
donor
hsvseroposit
diii
research
propos
administr
ganciclovir
prophylaxi
alon
hsct
recipi
requir
simultan
prophylaxi
cmv
hsv
hsct
ciii
ganciclovir
vitro
activ
cmv
hsv
although
ganciclovir
approv
use
hsv
valacyclovir
research
report
valacyclovir
use
prevent
hsv
among
hsct
recipi
ciii
howev
preliminari
data
demonstr
high
dose
valacyclovir
gday
associ
thrombot
thrombocytopen
purpurahemolyt
urem
syndrom
among
hsct
recipi
control
trial
data
among
hsct
recipi
limit
fda
approv
valacyclovir
use
among
recipi
physician
wish
use
valacyclovir
among
recipi
renal
impair
exercis
caution
decreas
dose
need
biii
appendix
foscarnet
substanti
renal
infusionrel
toxic
foscarnet
recommend
routin
hsv
prophylaxi
among
hsct
recipi
diii
famciclovir
present
data
regard
safeti
efficaci
famciclovir
among
hsct
recipi
limit
therefor
recommend
hsv
prophylaxi
famciclovir
made
hsv
prophylaxi
last
day
hsct
might
consid
person
frequent
recurr
hsv
ciii
appendix
acyclovir
use
phase
administr
hsvseroposit
autolog
recipi
like
experi
substanti
mucos
condit
regimen
ciii
antivir
prophylaxi
dose
modifi
use
among
children
appendix
publish
data
found
regard
valacyclovir
safeti
efficaci
among
children
hsct
candid
test
presenc
serum
antivzv
igg
antibodi
aiii
howev
test
reliabl
particularli
among
sever
immunosuppress
patient
research
recommend
past
histori
varicella
accompani
posit
titer
like
indic
presenc
immun
vzv
low
posit
titer
alon
hsct
candid
recipi
particularli
vzvseroneg
inform
potenti
serious
vzv
diseas
among
immunocompromis
person
advis
strategi
decreas
risk
vzv
exposur
aii
although
research
report
major
vzv
diseas
hsct
caus
reactiv
endogen
vzv
hsct
candid
recipi
vzvseroneg
vzvseroposit
immunocompromis
avoid
exposur
person
activ
vzv
infect
aii
hcw
famili
member
household
contact
visitor
healthi
report
histori
varicella
infect
vzvseroneg
receiv
vzv
vaccin
allow
visit
direct
contact
hsct
recipi
aiii
ideal
vzvsuscept
famili
member
household
contact
potenti
visitor
immunocompromis
hsct
recipi
vaccin
soon
decis
made
perform
hsct
vaccin
dose
dose
complet
week
condit
regimen
begin
week
day
hsct
perform
biii
hsct
recipi
candid
undergo
condit
therapi
avoid
contact
vzv
vaccin
recipi
experi
rash
vaccin
biii
rash
occur
usual
appear
day
vzv
vaccin
median
day
rang
day
person
commun
robert
g
sharrar
md
merck
co
inc
howev
date
seriou
diseas
report
among
immunocompromis
patient
transmiss
vzv
vaccin
viru
vzv
vaccin
strain
suscept
acyclovir
hsct
recipi
vzv
diseas
place
airborn
contact
precaut
aii
prevent
transmiss
hsct
recipi
contact
precaut
continu
skin
lesion
crust
airborn
precaut
institut
day
exposur
vzv
continu
day
last
exposur
day
postexposur
patient
receiv
varicellazost
immunoglobulin
vzig
ai
person
infect
vzv
infecti
rash
appear
vzig
vzvseroneg
hsct
recipi
administ
vzig
soon
possibl
ideal
within
hour
close
household
contact
person
either
chickenpox
shingl
hsct
recipi
immunocompet
ie
allogen
patient
month
hsct
month
hsct
immunosuppress
therapi
chronic
gvhd
aii
research
report
vzig
administr
vzv
exposur
describ
hsct
recipi
vzvseroposit
hsct
ciii
high
morbid
vzvassoci
diseas
among
sever
immunocompromis
hsct
recipi
data
publish
hsct
physician
administ
vzig
vzvseroneg
hsct
recipi
candid
undergo
condit
therapi
expos
vzv
vaccine
varicellalik
rash
biii
research
also
report
vzig
administr
situat
vzvseroposit
hsct
recipi
candid
undergo
condit
therapi
ciii
recommend
made
vaccine
might
unknowingli
incub
wildtyp
varicella
particularli
first
day
varicella
vaccin
vaccinestrain
vzv
rare
transmit
vzv
vaccine
vesicular
rash
postvaccin
vzvseroneg
hsct
recipi
candid
undergo
condit
therapi
close
expos
varicella
week
receiv
vzig
administ
anoth
dose
vzig
biii
research
also
recommend
vzig
administr
condit
vzvseroposit
hsct
recipi
candid
undergo
condit
therapi
ciii
antivir
drug
hsct
recipi
candid
undergo
condit
therapi
experi
vzvlike
rash
particularli
exposur
person
wildtyp
varicella
shingl
receiv
preemptiv
intraven
acyclovir
day
lesion
crust
biii
appendix
hsct
recipi
candid
undergo
condit
therapi
experi
vzvlike
rash
exposur
vzv
vaccine
rash
administ
intraven
acyclovir
preemptiv
prevent
sever
dissemin
vzv
diseas
bii
acyclovir
administ
day
lesion
crust
longterm
acyclovir
prophylaxi
prevent
recurr
vzv
infect
eg
first
month
hsct
routin
recommend
diii
howev
therapi
could
consid
use
among
hsct
recipi
sever
longterm
immunodefici
ciii
acyclovir
resist
occur
among
patient
hsct
physician
use
foscarnet
preemptiv
treatment
vzv
diseas
biii
research
report
valacyclovir
use
prevent
hsv
among
hsct
recipi
ciii
howev
preliminari
data
demonstr
high
dose
valacyclovir
gday
associ
thrombot
thrombocytopen
purpurahemolyt
urem
syndrom
among
hsct
recipi
control
trial
data
regard
hsct
recipi
limit
fda
approv
valacyclovir
use
among
hsct
recipi
physician
wish
use
valacyclovir
among
hsct
recipi
renal
impair
exercis
caution
decreas
dose
need
biii
appendix
data
found
demonstr
safeti
efficaci
preemptiv
treatment
famciclovir
herp
zoster
among
hsct
recipi
consequ
recommend
use
made
liveattenu
vzv
vaccin
vzv
vaccin
use
contraind
among
hsct
recipi
month
hsct
eiii
use
vzv
vaccin
among
hsct
recipi
restrict
research
protocol
recipi
month
hsct
presum
immunocompet
research
need
determin
safeti
immunogen
efficaci
vzv
vaccin
among
hsct
recipi
inactiv
vzv
vaccin
use
investig
among
hsct
recipi
howev
studi
need
recommend
regard
use
made
recommend
vzv
prevent
allogen
autolog
recipi
recommend
prevent
vzv
diseas
among
pediatr
adult
hsct
recipi
except
appropri
dose
adjust
vzig
made
pediatr
hsct
recipi
aiii
appendix
prevent
crv
exposur
critic
prevent
crv
diseas
prevent
nosocomi
crv
transmiss
hsct
recipi
hcw
alway
follow
hsct
infect
control
guidelin
aiii
minim
risk
crv
transmiss
hcw
visitor
upper
respiratori
infect
uri
symptom
restrict
contact
hsct
recipi
hsct
candid
undergo
condit
therapi
aiii
minimum
activ
clinic
surveil
crv
diseas
conduct
hospit
hsct
recipi
candid
undergo
condit
therapi
clinic
surveil
includ
daili
screen
sign
symptom
crv
eg
uri
lower
respiratori
infect
lri
aiii
viral
cultur
asymptomat
hsct
candid
unlik
use
hsct
recipi
uri
lri
symptom
place
contact
precaut
avoid
transmit
infect
hsct
candid
recipi
hcw
visitor
etiolog
ill
identifi
biii
optim
isol
precaut
modifi
need
etiolog
identifi
aiii
hsct
recipi
candid
famili
member
visitor
hcw
inform
regard
crv
infect
control
measur
potenti
sever
crv
infect
among
hsct
recipi
biii
physician
routin
conduct
culturebas
crv
surveil
among
hsct
recipi
howev
cost
effect
approach
evalu
influenza
vaccin
famili
member
close
household
contact
strongli
recommend
influenza
season
ie
octobermay
start
season
hsct
continu
month
hsct
ai
prevent
influenza
exposur
among
recipi
candid
famili
member
close
household
contact
hsct
recipi
remain
immunocompromis
month
hsct
continu
vaccin
annual
long
hsct
recipi
immunocompromis
persist
ai
season
influenza
vaccin
strongli
recommend
hcw
hsct
recipi
ai
hcw
famili
member
close
contact
hsct
recipi
receiv
influenza
vaccin
influenza
outbreak
receiv
amantadin
rimantadin
chemoprophylaxi
week
influenza
vaccin
bi
vaccine
experi
immunolog
respons
vaccin
strategi
like
prevent
transmiss
influenza
hcw
close
contact
hsct
recipi
could
prevent
influenza
transmiss
hsct
recipi
howev
nosocomi
outbreak
occur
influenza
strain
contain
avail
influenza
vaccin
healthi
famili
member
close
household
contact
hcw
hsct
recipi
candid
administ
influenza
chemoprophylaxi
amantadin
rimantadin
end
outbreak
biii
two
neuroaminidas
inhibitor
zanamivir
oseltamivir
approv
treatment
influenza
current
approv
prophylaxi
date
experi
limit
regard
use
zanamivir
oseltamivir
treatment
prophylaxi
influenza
among
hsct
set
howev
hcw
famili
member
close
contact
offer
neuroaminidas
inhibitor
eg
zanamivir
oseltamivir
use
strategi
outlin
previous
rimantadin
amantadin
toler
b
outbreak
strain
influenza
amantadin
rimantadineresist
c
outbreak
strain
influenza
b
bi
zanamivir
administ
person
age
year
oseltamivir
administ
person
age
year
patient
influenza
place
droplet
standard
precaut
aiii
prevent
transmiss
influenza
hsct
recipi
hcw
influenza
excus
patient
care
longer
infecti
aiii
hsct
physician
determin
etiolog
uri
hsct
recipi
candid
undergo
condit
therapi
possibl
respiratori
syncyti
viru
rsv
influenza
parainfluenza
adenoviru
uri
progress
seriou
lri
certain
crv
treat
biii
appropri
diagnost
sampl
includ
nasopharyng
wash
swab
aspir
throat
swab
bronchoalveolar
lavag
bal
fluid
hsct
candid
uri
symptom
time
condit
therapi
schedul
start
postpon
condit
regimen
uri
resolv
possibl
certain
uri
might
progress
lri
immunosuppress
biii
lifelong
season
influenza
vaccin
recommend
hsct
candid
recipi
begin
influenza
season
hsct
resum
month
hsct
biii
influenza
vaccin
administ
hsct
recipi
month
hsct
unlik
benefici
recommend
dii
hsct
recipi
month
hsct
receiv
chemoprophylaxi
amantadin
rimantadin
commun
nosocomi
influenza
outbreak
biii
drug
effect
influenza
b
addit
antiviralresist
strain
influenza
emerg
treatment
amantadin
rimantadin
transmiss
resist
strain
occur
outbreak
hsct
recipi
month
hsct
month
hsct
still
substanti
immunocompromis
ie
receiv
immunosuppress
therapi
relaps
underli
diseas
gvhd
yet
receiv
current
influenza
vaccin
vaccin
influenza
immedi
biii
addit
allow
suffici
time
patient
experi
immunolog
respons
influenza
vaccin
chemoprophylaxi
amantadin
rimantadin
use
hsct
recipi
week
vaccin
nosocomi
commun
influenza
outbreak
ciii
influenza
chemoprophylaxi
amantadin
rimantadin
recommend
influenza
aexpos
hsct
recipi
month
hsct
month
hsct
substanti
immunocompromis
regardless
vaccin
histori
like
suboptim
immunolog
respons
influenza
vaccin
howev
recommend
regard
chemoprophylaxi
made
lack
data
prevent
sever
diseas
earli
preemptiv
therapi
amantadin
rimantadin
report
hsct
recipi
unexplain
acut
uri
lri
symptom
commun
nosocomi
outbreak
influenza
howev
effect
prevent
influenzarel
complic
safeti
strategi
evalu
among
hsct
recipi
therefor
data
insuffici
make
recommend
neuroaminidas
inhibitor
zanimivir
oseltamivir
intraven
aerosol
ribavirin
combin
drug
therapi
eg
rimantadin
amantadin
ribavirin
interferon
propos
investig
preemptiv
treatment
prevent
sever
influenza
diseas
among
hsct
recipi
howev
lack
data
recommend
use
strategi
among
hsct
recipi
made
respiratori
secret
hospit
hsct
candid
recipi
experi
sign
symptom
crv
infect
test
promptli
viral
cultur
rapid
diagnost
test
rsv
biii
two
diagnost
sampl
taken
day
apart
identifi
respiratori
pathogen
despit
persist
respiratori
symptom
bal
test
advis
biii
test
critic
high
morbid
case
fatal
rsv
diseas
among
hsct
recipi
hsct
recipi
particularli
preengraft
highest
risk
sever
rsv
pneumonia
ill
diagnos
earli
ie
rsv
uri
ill
treat
aggress
prevent
fatal
rsv
diseas
biii
although
definit
uniformli
effect
preemptiv
therapi
rsv
infect
among
hsct
recipi
identifi
certain
strategi
propos
includ
use
aerosol
ribavirin
rsv
antibodi
ie
passiv
immun
high
rsvtiter
ivig
rsv
immunoglobulin
combin
aerosol
ribavirin
rsv
monoclon
antibodi
clinic
trial
current
underway
evalu
efficaci
strategi
recommend
regard
optim
method
rsv
prevent
preemptiv
therapi
made
limit
data
current
data
support
use
intraven
ribavirin
preemptiv
therapi
rsv
pneumonia
among
hsct
recipi
diii
nocommerci
licens
vaccin
rsv
current
avail
adenoviru
immunoprophylaxi
chemoprophylaxi
preemptiv
treatment
parainfluenza
viru
adenoviru
infect
among
hsct
recipi
propos
howev
recommend
made
guidelin
insuffici
data
commerci
licens
vaccin
parainfluenza
adenoviru
current
avail
recommend
prevent
crv
infect
recurr
allogen
autolog
recipi
gener
recommend
appli
children
adult
appropri
adjust
antivir
drug
influenza
vaccin
dose
children
appendix
pediatr
hsct
recipi
candid
age
month
annual
season
influenza
vaccin
recommend
hsct
biii
children
age
year
receiv
influenza
vaccin
first
time
requir
two
dose
administ
month
apart
ai
healthi
children
receiv
influenza
vaccin
first
time
might
gener
protect
antibodi
week
receipt
second
dose
influenza
vaccin
therefor
influenza
outbreak
pediatr
recipi
age
year
month
hsct
receiv
first
influenza
vaccin
administ
week
influenza
chemoprophylaxi
first
dose
influenza
vaccin
biii
appendix
amantadin
rimantadin
fdaapprov
children
age
year
diii
prevent
rsv
diseas
research
report
substitut
rsvivig
ivig
rsv
season
ie
novemberapril
pediatr
recipi
ie
children
age
year
receiv
routin
ivig
therapi
ie
hypogammaglobulinemia
ciii
appendix
research
report
pediatr
recipi
rsv
consid
preemptiv
therapi
eg
uri
earli
lri
aerosol
ribavirin
ciii
although
therapi
remain
controversi
appendix
droplet
contact
precaut
durat
ill
requir
pediatr
recipi
durat
adenoviru
aiii
limit
data
found
demonstr
extent
prevent
fungal
exposur
effect
prevent
infect
diseas
howev
hsct
recipi
candid
undergo
condit
therapi
advis
avoid
contact
certain
area
substanc
includ
food
might
increas
patient
risk
fungal
exposur
cii
specif
precaut
includ
avoid
area
high
dust
exposur
eg
excav
site
area
build
construct
renov
chicken
coop
cave
occup
involv
soil
food
contain
mold
eg
blue
chees
growth
factor
eg
gmcsf
gcsf
shorten
durat
neutropenia
hsct
howev
data
found
indic
growth
factor
effect
reduc
attack
rate
invas
fungal
diseas
therefor
recommend
use
growth
factor
sole
prophylaxi
invas
fungal
diseas
made
topic
antifung
drug
appli
skin
mucosa
eg
nystatin
clotrimazol
might
reduc
fungal
colon
area
applic
howev
agent
proven
prevent
gener
local
invas
dissemin
yeast
infect
eg
candidiasi
mold
infect
eg
aspergillosi
recommend
prophylaxi
dii
perform
fungal
surveil
cultur
indic
asymptomat
hsct
recipi
dii
cultur
obtain
symptomat
hsct
recipi
biii
invas
candidiasi
usual
caus
dissemin
endogen
candida
speci
colon
patient
gastrointestin
tract
consequ
method
prevent
exogen
yeast
exposur
usual
prevent
invas
yeast
infect
hsct
howev
candida
speci
carri
hand
hcw
other
contact
hsct
recipi
follow
appropri
handwash
practic
safeguard
patient
exposur
aiii
allogen
recipi
administ
fluconazol
prophylaxi
prevent
invas
diseas
fluconazolesuscept
candida
speci
neutropenia
particularli
among
center
albican
predomin
caus
invas
fungal
diseas
preengraft
ai
appendix
candidiasi
occur
phase
fluconazol
mgday
mouth
intraven
administ
day
hsct
engraft
aii
howev
fluconazol
effect
certain
candida
speci
includ
krusei
glabrata
therefor
recommend
prevent
di
studi
need
determin
optim
durat
fluconazol
prophylaxi
preliminari
studi
report
lowdos
fluconazol
prophylaxi
mgday
mouth
among
neutropen
patient
variabl
efficaci
prevent
candidiasi
therefor
therapi
recommend
hsct
recipi
dii
oral
nonabsorb
antifung
drug
includ
oral
amphotericin
b
mg
suspens
everi
hour
nystatin
clotrimazol
troch
might
reduc
superfici
colon
control
local
mucos
candidiasi
demonstr
reduc
invas
candidiasi
ciii
hsct
candid
candidemia
invas
candidiasi
safe
receiv
transplant
infect
diagnos
earli
treat
immedi
aggress
amphotericin
b
altern
appropri
dose
fluconazol
organ
suscept
b
evid
diseas
control
report
eg
serial
comput
tomographi
scan
transplant
biii
patient
continu
receiv
therapeut
dose
appropri
antifung
drug
throughout
phase
bii
care
review
clinic
laboratori
serial
comput
tomographi
scan
verifi
resolut
candidiasi
bii
autolog
recipi
gener
overal
lower
risk
invas
fungal
infect
allogen
recipi
certain
autolog
recipi
requir
routin
antiyeast
prophylaxi
diii
howev
research
recommend
administ
antiyeast
prophylaxi
subpopul
autolog
recipi
underli
hematolog
malign
eg
lymphoma
leukemia
prolong
neutropenia
mucos
damag
intens
condit
regimen
graft
manipul
receiv
fludarabin
recent
biii
recommend
regard
prevent
invas
yeast
infect
among
pediatr
adult
hsct
recipi
except
appropri
dose
adjust
prophylact
drug
made
pediatr
recipi
appendix
nosocomi
mold
infect
among
hsct
recipi
result
primarili
respiratori
exposur
direct
contact
fungal
spore
ongo
hospit
construct
renov
associ
increas
risk
nosocomi
mold
infect
particularli
aspergillosi
among
sever
immunocompromis
patient
therefor
whenev
possibl
hsct
recipi
remain
immunocompromis
avoid
hospit
construct
renov
area
aiii
construct
new
hsct
center
renov
old
one
hospit
planner
ensur
room
hsct
patient
adequ
capac
minim
fungal
spore
count
use
higheffici
particul
air
hepa
filtrat
biii
direct
room
airflow
ie
posit
air
pressur
patient
room
relat
corridor
air
pressur
air
patient
room
flow
corridor
biii
correctli
seal
room
includ
correctli
seal
window
electr
outlet
biii
high
rate
room
air
exchang
ie
air
chang
hour
biii
barrier
patient
care
renov
construct
area
eg
seal
plastic
prevent
dust
enter
patient
care
area
imperm
aspergillu
speci
biii
addit
hsct
center
clean
care
particularli
hospit
renov
construct
avoid
expos
hsct
recipi
candid
mold
spore
biii
regimen
report
clearli
effect
superior
prevent
aspergillosi
therefor
recommend
made
studi
need
determin
optim
strategi
aspergillosi
prevent
moderatedos
mgkgday
amphotericin
b
lowdos
mgkgday
amphotericin
b
intranas
amphotericin
b
spray
lipid
formul
amphotericin
b
aerosol
amphotericin
b
administ
aspergillosi
prophylaxi
data
limit
regard
safeti
efficaci
formul
among
hsct
recipi
addit
itraconazol
capsul
recommend
fungal
prophylaxi
among
hsct
recipi
dii
three
reason
first
itraconazol
capsul
poorli
absorb
gastrointestin
particularli
among
patient
fast
receiv
cytotox
agent
second
person
take
itraconazol
capsul
achiev
steadyst
serum
level
week
achiev
level
lower
averag
aspergillu
speci
minimum
inhibitori
concentr
mic
among
hsct
recipi
third
itraconazol
advers
interact
drug
eg
antiepilept
rifampin
oral
hypoglycem
proteas
inhibitor
vinca
alkaloid
cyclosporin
methylprednisolon
warfarinlik
anticoagul
trial
assess
efficaci
recent
licens
cyclodextrin
oral
solut
intraven
formul
itraconazol
prevent
invas
fungal
diseas
among
hsct
recipi
progress
howev
recommend
regard
use
aspergillu
speci
infect
prophylaxi
made
hsct
recipi
whose
respiratori
specimen
cultur
posit
aspergillu
speci
acut
invas
aspergillosi
diagnos
presumpt
treat
preemptiv
aggress
eg
intraven
amphotericin
aiii
risk
aspergillosi
recurr
high
among
allogen
recipi
preexist
invas
aspergillosi
previous
allogen
hsct
avoid
among
person
uncontrol
proven
aspergillosi
howev
hsct
center
personnel
recent
report
success
allogen
autolog
hsct
among
limit
number
person
success
treat
prior
invas
pulmonari
aspergillosi
limit
data
recommend
regard
strategi
prevent
aspergillosi
recurr
made
although
possibl
caus
pcp
reactiv
latent
infect
among
immunocompromis
person
case
persontoperson
transmiss
pcp
report
gener
standard
precaut
use
patient
pcp
biii
research
report
patient
pcp
isol
contact
precaut
use
evid
exist
persontoperson
transmiss
institut
ciii
subject
remain
controversi
data
publish
hsct
recipi
avoid
exposur
person
pcp
ciii
physician
prescrib
pcp
prophylaxi
allogen
recipi
throughout
period
immunocompromis
engraft
prophylaxi
administ
engraft
month
hsct
aii
patient
month
hsct
durat
immunosuppress
receiv
immunosuppress
therapi
eg
prednison
cyclosporin
ai
b
chronic
gvhd
bii
howev
pcp
prophylaxi
initi
engraft
engraft
delay
ciii
research
report
addit
cours
pcp
prophylaxi
hsct
ie
day
day
ciii
prefer
pcp
prophylaxi
tmpsmz
aii
howev
tmpsmz
administ
engraft
associ
myelosuppress
could
delay
engraft
patient
might
experi
sensit
drug
everi
effort
made
keep
patient
drug
includ
assess
desensit
therapi
although
data
regard
techniqu
among
hsct
recipi
limit
patient
toler
tmpsmz
physician
choos
use
altern
pcp
prophylaxi
regimen
eg
dapson
biii
use
aerosol
pentamidin
associ
lowest
pcp
prevent
rate
use
agent
toler
atovaquon
possibl
altern
drug
pcp
prophylaxi
among
dapson
intoler
person
hiv
infect
howev
recommend
regard
use
atovaquon
among
hsct
recipi
made
lack
data
although
data
limit
concomit
use
leucovorin
folin
acid
tmpsmz
recommend
diii
patient
histori
pcp
regard
contraind
hsct
diii
recurr
pcp
among
hsct
recipi
rare
howev
patient
continu
immunosuppress
remain
pcp
prophylaxi
immunosuppress
resolv
ai
regimen
recommend
prevent
toxoplasmosi
recurr
among
hsct
recipi
ie
tmpsmz
also
prevent
pcp
recurr
pcp
prophylaxi
consid
autolog
recipi
underli
hematolog
malign
ie
lymphoma
leukemia
receiv
intens
condit
regimen
graft
manipul
recent
receiv
fludarabin
biii
pcp
prophylaxi
administ
month
hsct
substanti
immunosuppress
immunosuppress
therapi
eg
steroid
persist
ciii
use
pcp
prophylaxi
among
autolog
recipi
controversi
ciii
gener
indic
pcp
prophylaxi
among
children
adult
pediatr
dose
use
appendix
hsct
recipi
provid
inform
regard
strategi
reduc
risk
toxoplasma
speci
exposur
research
report
potenti
donor
allogen
hsct
test
gondii
antibodi
use
fdalicens
approv
screen
test
includ
igg
antibodi
test
gondii
report
transmit
leukocyt
transfus
hsct
ciii
toxoplasmosi
among
hsct
recipi
caus
diseas
reactiv
research
report
candid
allogen
hsct
test
igg
antibodi
determin
whether
risk
diseas
reactiv
hsct
ciii
howev
valu
test
controversi
limit
number
patient
seroneg
gondii
pretranspl
experienc
infect
posttranspl
test
perform
fdalicens
approv
screen
test
use
research
recommend
toxoplasmosi
prophylaxi
seroposit
allogen
recipi
activ
gvhd
prior
histori
toxoplasm
chorioretin
data
demonstr
efficaci
limit
ciii
optim
prophylact
regimen
toxoplasmosi
among
hsct
recipi
determin
propos
drug
tmpsmz
bii
although
allogen
recipi
experienc
breakthrough
clinic
diseas
despit
tmpsmz
prophylaxi
patient
tmpsmzintoler
combin
clindamycin
pyramethamin
leucovorin
substitut
gondii
prophylaxi
appendix
therapi
toxoplasmosi
hsct
recipi
continu
receiv
suppress
dose
tmpsmz
altern
regimen
durat
immunosuppress
biii
appendix
recipi
autolog
transplant
neglig
risk
toxoplasmosi
reactiv
prophylaxi
screen
toxoplasmosi
infect
recommend
patient
diii
indic
toxoplasmosi
prophylaxi
among
children
adult
pediatr
dose
use
among
children
appendix
allogen
recipi
avoid
contact
outhous
cutan
exposur
soil
surfac
might
contamin
human
fece
aiii
allogen
recipi
work
set
eg
hospit
institut
could
expos
fecal
matter
wear
glove
work
patient
area
potenti
fecal
contamin
aiii
travel
resid
histori
obtain
patient
hsct
determin
exposur
highrisk
area
eg
moist
temper
area
tropic
subtrop
southeastern
unit
state
europ
biii
hsct
candid
unexplain
peripher
eosinophilia
resid
travel
area
endem
strongyloidiasi
even
distant
past
screen
asymptomat
strongyloidiasi
hsct
biii
serolog
test
enzymelink
immunosorb
assay
prefer
screen
method
sensit
specif
biii
fdalicens
approv
screen
test
use
although
stool
examin
strongyloidiasi
specif
sensit
obtain
stool
examin
sensit
obtain
concentr
stool
exam
best
total
stool
examin
perform
serolog
test
unavail
strongyloidiasi
clinic
suspect
seroneg
patient
biii
hsct
candid
whose
screen
test
hsct
posit
strongyloid
speci
unexplain
eosinophilia
travel
resid
histori
indic
exposur
strongyloid
stercorali
empir
treat
transplant
prefer
ivermectin
biii
even
seroneg
stoolneg
appendix
prevent
recurr
among
hsct
candid
parasitolog
confirm
strongyloidiasi
cure
therapi
verifi
consecut
neg
stool
examin
proceed
hsct
aiii
data
insuffici
recommend
drug
prophylaxi
regimen
hsct
prevent
recurr
strongyloidiasi
hsct
recipi
strongyloidiasi
hsct
monitor
care
sign
symptom
recurr
infect
month
treatment
biii
hyperinfect
strongyloidiasi
report
autolog
hsct
howev
screen
precaut
use
among
autolog
recipi
biii
indic
empir
treatment
strongyloidiasi
hsct
among
children
adult
except
children
weigh
kg
prefer
drug
thiabendazol
biii
appendix
hsct
physician
awar
trypanosoma
cruzi
etiolog
agent
chaga
diseas
transmit
congenit
blood
transfus
possibl
hsct
addit
treatment
person
infect
tr
cruzi
alway
effect
even
acut
stage
infect
therefor
potenti
donor
born
receiv
blood
transfus
ever
live
month
chaga
diseas
endem
area
eg
part
south
central
america
mexico
screen
serolog
antitr
cruzi
serum
igg
antibodi
biii
person
live
month
chagasendem
area
highrisk
live
condit
eg
extens
exposur
chaga
diseas
vector
reduviid
bug
live
dwell
mud
wall
unmil
log
stick
thatch
roof
also
screen
evid
tr
cruzi
infect
biii
chaga
diseas
transmit
congenit
research
report
person
extens
multigener
matern
famili
histori
cardiac
diseas
eg
cardiomegali
arrhythmia
screen
serolog
serum
igg
antitr
cruzi
antibodi
ciii
decreas
risk
misdiagnosi
falseposit
falseneg
serolog
test
tr
cruzi
screen
consist
convent
serolog
test
eg
enzym
immunoassay
indirect
hemagglutin
indirect
fluoresc
antibodi
convent
serolog
test
follow
confirmatori
serolog
test
eg
radioimmunoprecipit
assay
biii
person
activ
chaga
diseas
serv
hsct
donor
diii
research
also
recommend
deferr
hsct
donat
past
histori
chaga
diseas
ciii
hsct
candid
risk
infect
tr
cruzi
screen
serum
igg
antitr
cruzi
antibodi
biii
tr
cruzi
seroposit
contraind
hsct
howev
acut
ill
occur
tr
cruziseroposit
hsct
recipi
particularli
neutropenia
tr
cruzi
reactiv
includ
differenti
diagnosi
biii
research
propos
use
beznidazol
nifurtimox
preemptiv
therapi
prophylaxi
recurr
tr
cruzi
among
seroposit
hsct
recipi
insuffici
data
found
make
recommend
recommend
autolog
allogen
recipi
howev
recurr
chaga
diseas
probabl
less
like
occur
among
autolog
recipi
shorter
durat
immunosuppress
recommend
among
children
adult
hsct
center
personnel
follow
publish
guidelin
hospit
room
design
ventil
biii
hsct
center
also
prevent
bird
gain
access
hospit
airintak
duct
aii
allogen
recipi
place
room
air
exchang
hour
pointofus
hepa
filter
capabl
remov
particl
diamet
aiii
correct
filtrat
critic
hsct
center
ongo
construct
renov
portabl
hepa
filter
use
adjunct
primari
ventil
system
must
place
central
patient
room
space
avail
around
surfac
allow
free
air
circul
biii
need
environment
hepa
filtrat
autolog
recipi
establish
howev
hepafilt
room
evalu
autolog
recipi
experi
prolong
neutropenia
substanti
risk
factor
nosocomi
aspergillosi
ciii
laminar
air
flow
laf
room
contain
filter
air
move
parallel
unidirect
flow
air
enter
room
one
wall
exit
room
opposit
wall
although
laf
demonstr
protect
patient
infect
aspergillosi
outbreak
relat
hospit
construct
valu
routin
laf
room
use
hsct
recipi
doubt
substanti
overal
surviv
benefit
report
laf
room
prefer
allogen
recipi
aplast
anemia
hlaident
sibl
donor
use
regular
room
associ
mortal
rate
approxim
four
time
higher
recipi
treat
laf
room
howev
surviv
aplast
anemia
hsct
recipi
late
exce
report
earli
studi
done
determin
whether
hsct
recipi
aplast
anemia
still
improv
surviv
rate
treat
laf
room
therefor
hsct
center
need
construct
laf
room
hsct
recipi
use
laf
room
avail
option
cii
hospit
room
direct
airflow
air
intak
occur
one
side
room
air
exhaust
occur
opposit
side
biii
hospit
room
also
wellseal
eg
around
window
electr
outlet
biii
provid
consist
posit
pressur
recipi
room
hsct
center
maintain
consist
pressur
differenti
patient
room
hallway
anteroom
pa
ie
inch
water
gaug
biii
gener
hospit
room
hsct
recipi
posit
room
air
pressur
compar
adjoin
hallway
toilet
anteroom
present
anteroom
posit
air
pressur
compar
hallway
except
hsct
recipi
activ
diseas
airborn
transmiss
eg
pulmonari
laryng
mycobacteria
tuberculosi
tb
measl
hsct
patient
place
neg
isol
room
biii
room
anteroom
recommend
patient
biii
whenev
possibl
hsct
center
selfclos
door
maintain
constant
pressur
differenti
among
hsct
recipi
room
anteroom
avail
hallway
biii
enabl
nurs
staff
observ
hsct
recipi
even
door
close
window
instal
either
door
wall
hsct
recipi
room
ciii
hsct
center
provid
backup
emerg
power
redund
airhandl
pressur
system
maintain
constant
number
air
exchang
room
pressur
center
central
ventil
system
shut
mainten
repair
biii
addit
infect
control
personnel
work
mainten
personnel
develop
protocol
protect
hsct
center
time
burst
mold
spore
might
occur
airhandl
system
restart
routin
mainten
shutdown
biii
hospit
construct
renov
associ
increas
risk
nosocomi
fungal
infect
particularli
aspergillosi
among
sever
immunocompromis
patient
therefor
person
respons
hsct
center
construct
renov
consult
publish
recommend
regard
environment
control
construct
aiii
whenev
possibl
hsct
recipi
hcw
visitor
avoid
construct
renov
area
aiii
also
equip
suppli
use
hsct
recipi
hcw
expos
construct
renov
area
plan
construct
renov
hsct
center
includ
plan
intensifi
aspergillosiscontrol
measur
aiii
construct
renov
infect
control
plan
committe
includ
engin
architect
housekeep
staff
infect
control
personnel
director
hsct
center
administr
safeti
offic
biii
construct
new
hsct
center
planner
ensur
patient
room
adequ
capac
minim
fungal
spore
count
follow
room
ventil
recommend
outdoor
construct
demolit
intak
air
seal
biii
possibl
filter
check
frequent
addit
protect
hsct
patient
care
area
fire
drill
emerg
weather
strip
place
around
stairwel
door
altern
stairwel
air
filter
level
safeti
adjac
hospit
air
biii
fals
ceil
avoid
whenev
possibl
bii
use
fals
ceil
avoid
area
fals
ceil
vacuum
routin
minim
dust
therefor
fungal
exposur
patient
biii
hospit
construct
renov
hospit
construct
rigid
dustproof
barrier
airtight
seal
patient
care
construct
renov
area
prevent
dust
enter
patient
care
area
barrier
ie
seal
drywal
imperm
aspergillu
speci
biii
impervi
barrier
creat
around
construct
renov
area
patient
move
area
renov
construct
complet
area
clean
appropri
biii
hsct
center
direct
pedestrian
traffic
occur
near
construct
renov
area
away
patient
care
area
limit
open
close
door
barrier
might
caus
dust
dispers
entri
contamin
air
track
dust
patient
area
particularli
hsct
center
biii
possibl
specif
corridor
entranc
exit
dedic
construct
use
elev
patient
access
also
dedic
construct
use
construct
worker
whose
cloth
might
contamin
aspergillu
speci
spore
use
construct
elev
avoid
contact
patient
patient
care
area
elev
nonconstruct
area
biii
hospit
construct
renov
area
neg
air
pressur
rel
adjac
patient
care
area
contraind
exist
pressur
differenti
biii
ideal
air
construct
renov
area
exhaust
outsid
hospit
biii
recircul
hepafilt
first
biii
research
propos
hsct
recipi
wear
respir
prevent
mold
exposur
transport
near
hospit
construct
renov
area
ciii
respir
regard
effect
aerosol
howev
maxim
effect
respir
must
fittest
user
must
train
correct
personnel
fittest
train
respir
reliabl
reduc
aerosol
exposur
without
fittest
train
aerosol
exposur
would
reduc
necessarili
patient
use
toler
respir
research
propos
use
power
air
purifi
respir
use
patient
wheelchair
limit
power
air
purifi
respir
includ
cost
appropri
young
children
infant
gener
limit
use
respir
commerci
avail
respir
includ
test
specif
efficaci
reduc
exposur
aspergillu
speci
hospit
construct
renov
area
studi
done
assess
use
accept
use
respir
among
hsct
recipi
standard
surgic
mask
provid
neglig
protect
mold
spore
recommend
indic
diii
newli
construct
renov
area
clean
patient
allow
enter
aiii
decontamin
fungalcontamin
area
extract
replac
done
use
biii
also
area
fals
ceil
locat
adjac
construct
area
vacuum
biii
addit
ventil
direct
airflow
room
pressur
test
correctli
adjust
patient
allow
enter
biii
hsct
center
clean
timesday
special
attent
dust
control
biii
exhaust
vent
window
sill
horizont
surfac
clean
cloth
mop
head
premoisten
fdaor
environment
protect
agenc
epa
regist
hospit
disinfect
biii
thorough
clean
construct
activ
includ
minor
renov
project
critic
biii
hsct
center
personnel
prohibit
exposur
patient
activ
vacuum
floor
carpet
vacuum
could
caus
aerosol
fungal
spore
eg
aspergillu
speci
aiii
accordingli
door
patient
room
close
vacuum
hsct
center
corridor
vacuum
cleaner
use
hsct
center
fit
hepa
filter
fdaor
eparegist
disinfect
use
daili
environment
disinfect
wet
vacuum
perform
hsct
center
biii
hsct
center
provid
care
infant
phenol
disinfect
use
clean
floor
compound
dilut
accord
product
label
phenol
compound
use
clean
basinet
incub
diii
water
leak
clean
repair
soon
possibl
within
hour
prevent
mold
prolifer
floor
wall
cover
ceil
tile
cabinetri
around
hsct
patient
care
area
biii
cleanup
repair
delay
hour
water
leak
involv
materi
assum
contain
fungi
handl
accordingli
use
moistur
meter
detect
water
penetr
wall
use
whenev
possibl
guid
decisionmak
biii
exampl
wall
moistur
content
hour
water
penetr
remov
biii
design
select
furnish
focu
creat
maintain
dustfre
environ
floor
finish
ie
wall
cover
window
shade
countertop
use
hsct
center
scrubbabl
nonpor
easili
disinfect
collect
minim
dust
biii
hsct
center
personnel
follow
publish
guidelin
hospit
isol
practic
includ
cdc
guidelin
prevent
nosocomi
infect
aiii
howev
efficaci
specif
isol
barrier
precaut
prevent
nosocomi
infect
among
hsct
recipi
evalu
hsct
recipi
place
privat
ie
singlepati
room
biii
contact
bodi
fluid
anticip
standard
precaut
follow
aiii
precaut
includ
hand
wash
wear
appropri
glove
surgic
mask
eye
face
protect
gown
procedur
activ
like
gener
splash
spray
blood
bodi
fluid
secret
excret
caus
soil
cloth
indic
hsct
recipi
also
place
airborn
droplet
contact
precaut
addit
standard
precaut
aiii
care
observ
isol
precaut
critic
prevent
transmiss
infecti
agent
among
hsct
recipi
hcw
visitor
hsct
recipi
physician
caution
hsct
recipi
might
prolong
episod
excret
organ
eg
cmv
research
propos
hsct
recipi
wear
surgic
mask
glove
exit
hospit
room
engraft
ciii
hsct
recipi
immunocompromis
phase
iiii
immun
system
recoveri
candid
undergo
condit
therapi
minim
time
spent
crowd
area
hospit
eg
wait
area
elev
biii
minim
potenti
exposur
person
crv
infect
hand
wash
singlemost
critic
effect
procedur
prevent
nosocomi
infect
person
particularli
hcw
wash
hand
enter
leav
room
hsct
recipi
candid
undergo
condit
therapi
direct
contact
patient
regardless
whether
soil
patient
environ
object
ai
hsct
recipi
encourag
practic
safe
hand
hygien
eg
wash
hand
eat
use
toilet
touch
wound
biii
hand
wash
done
antimicrobi
soap
water
aiii
altern
use
hygien
hand
rub
anoth
accept
mean
maintain
hand
hygien
glove
worn
hcw
put
patient
room
hand
wash
discard
patient
room
wash
hand
exit
room
worn
glove
alway
chang
patient
soil
touch
clean
area
eg
chang
glove
touch
perineum
go
clean
area
aiii
appropri
glove
use
person
handl
potenti
contamin
biolog
materi
aii
item
worn
hand
finger
eg
ring
artifici
nail
adhes
bandag
strip
creat
nidu
pathogen
organ
difficult
clean
thu
hcw
avoid
wear
item
whenev
possibl
bii
hsct
center
personnel
steril
disinfect
maintain
equip
devic
use
eparegist
compound
direct
establish
guidelin
aiii
hsct
center
personnel
monitor
open
unopen
wounddress
suppli
eg
adhes
bandag
surgic
elast
adhes
tape
detect
mold
contamin
prevent
subsequ
cutan
transmiss
patient
bii
monitor
consist
discard
bandag
wound
dress
date
damag
packag
visual
contamin
construct
debri
moistur
biii
arm
board
use
provid
support
intraven
line
steril
dress
materi
use
arm
board
chang
frequent
eg
daili
biii
addit
unsteril
tongu
depressor
insert
piec
foam
tube
use
splint
intraven
arteri
cathet
site
associ
outbreak
fatal
invas
nosocomi
rhizopu
microsporu
among
preterm
ie
lowbirthweight
infant
dii
hsct
center
instal
carpet
hallway
outsid
dii
patient
room
diii
contamin
carpet
associ
outbreak
aspergillosi
among
hsct
recipi
although
date
exposur
plant
flower
conclus
report
caus
fungal
infect
among
hsct
recipi
research
strongli
recommend
plant
dri
fresh
flower
allow
room
hospit
hsct
candid
undergo
condit
therapi
hsct
recipi
phase
iiii
immun
system
recoveri
aspergillu
speci
isol
soil
pot
ornament
plant
eg
cacti
surfac
dri
flower
arrang
fresh
flower
play
area
pediatr
hsct
recipi
candid
undergo
condit
therapi
clean
disinfect
timesweek
need
biii
toy
game
video
kept
clean
disinfect
allow
hsct
center
biii
hsct
center
follow
publish
recommend
wash
disinfect
toy
biii
hsct
center
toy
game
video
routin
thoroughli
wash
wipe
brought
hsct
center
thereaft
time
week
need
use
nontox
fdaor
eparegist
disinfect
follow
water
rins
biii
cloth
plush
toy
wash
hot
cycl
wash
machin
dryclean
timesweek
need
biii
altern
machin
wash
cold
cycl
accept
laundri
chemic
cold
water
wash
use
proper
concentr
hard
plastic
toy
scrub
warm
soapi
water
use
brush
clean
crevic
rins
clean
water
immers
mild
bleach
solut
made
fresh
daili
minut
rins
allow
air
dri
altern
hard
plastic
toy
wash
dishwash
hot
cycl
wash
machin
biii
broviac
doll
disassembl
upon
complet
play
wash
nontox
fdaor
eparegist
disinfect
rins
tap
water
allow
air
dri
children
allow
play
biii
toy
wash
disinfect
dryclean
use
avoid
biii
infant
toddler
children
put
toy
mouth
share
toy
diii
children
isol
research
recommend
follow
dispos
play
item
offer
whenev
possibl
biii
return
washabl
toy
use
isol
room
pediatr
play
room
use
anoth
child
clean
previous
describ
biii
child
taken
isol
toy
game
video
use
period
isol
might
serv
fomit
infect
thoroughli
disinfect
nontox
fdaor
eparegist
disinfect
biii
use
isol
room
cloth
plush
toy
place
plastic
bag
separ
unus
toy
cloth
plush
toy
use
isol
room
wash
wash
machin
dryclean
use
nonisol
room
biii
toy
disinfect
dryclean
use
isol
room
discard
biii
waterretain
bath
toy
associ
outbreak
pseudomona
aeruginosa
pediatr
oncolog
ward
therefor
toy
use
immunocompromis
hsct
recipi
candid
dii
occup
physic
therapi
item
clean
disinfect
previous
describ
biii
soilbas
materi
eg
clay
pot
soil
avoid
biii
hsct
center
personnel
written
comprehens
polici
regard
immun
vaccin
polici
meet
current
cdc
advisori
committe
immun
practic
healthcar
infect
control
practic
advisori
committe
recommend
biii
immun
need
prevent
transmiss
vaccineprevent
diseas
hsct
recipi
candid
undergo
condit
therapi
hcw
diseas
transmiss
air
droplet
direct
contact
eg
vzv
infecti
gastroenter
hsv
lesion
lip
finger
uri
restrict
patient
contact
temporarili
reassign
duti
ai
hsct
center
personnel
follow
publish
recommend
regard
durat
work
restrict
hcw
infecti
diseas
biii
hsct
center
hcw
bloodborn
virus
eg
hiv
hepat
b
c
virus
restrict
patient
contact
diii
long
perform
procedur
pose
high
risk
injuri
could
result
patient
exposur
hcw
blood
bodi
fluid
work
exclus
polici
design
encourag
hcw
report
ill
exposur
aii
hospit
written
polici
screen
hsct
center
visitor
particularli
children
potenti
infecti
condit
screen
perform
clinic
train
hcw
bii
visitor
might
communic
infecti
diseas
eg
uri
flulik
ill
recent
exposur
communic
diseas
activ
shingl
rash
whether
cover
vzvlike
rash
within
week
receiv
live
attenu
vzv
vaccin
histori
receiv
oral
polio
vaccin
within
previou
week
allow
hsct
center
allow
direct
contact
hsct
recipi
candid
undergo
condit
therapi
aii
absolut
minimum
age
requir
hsct
center
visitor
exist
howev
visitor
must
abl
understand
follow
appropri
hand
broviac
doll
use
demonstr
medic
procedur
eg
insert
cathet
children
lessen
fear
wash
isol
precaut
aiii
number
hsct
center
visitor
one
time
restrict
number
permit
nurs
staff
perform
appropri
screen
contagi
diseas
adequ
instruct
supervis
hand
wash
glove
mask
use
biosafeti
precaut
biii
optim
skin
care
hsct
recipi
take
daili
shower
bath
transplant
biii
use
mild
soap
biii
skin
care
neutropenia
also
includ
daili
inspect
skin
site
like
portal
infect
eg
perineum
intravascular
access
site
biii
hsct
recipi
candid
undergo
condit
therapi
maintain
good
perin
hygien
minim
loss
skin
integr
risk
infect
biii
facilit
precaut
hsct
center
personnel
develop
protocol
patient
perin
care
includ
recommend
gentl
thorough
perin
clean
bowel
movement
thorough
dri
perineum
urin
biii
femal
alway
wipe
perineum
front
back
use
toilet
prevent
fecal
contamin
urethra
urinari
tract
infect
aiii
moreov
prevent
vagin
irrit
menstruat
immunocompromis
hsct
recipi
use
tampon
diii
avoid
risk
cervic
vagin
abras
addit
use
rectal
thermomet
enema
suppositori
rectal
exam
contraind
among
hsct
recipi
avoid
skin
mucos
breakdown
diii
hsct
candid
caregiv
educ
regard
import
maintain
good
oral
dental
hygien
least
first
year
hsct
reduc
risk
oral
dental
infect
aiii
exampl
hsct
candid
inform
establish
best
possibl
periodont
health
hsct
substanti
step
avoid
shortand
longterm
oral
infect
mainten
safe
oral
hygien
hsct
minim
sever
infect
facilit
heal
mucos
particularli
engraft
biii
hsct
candid
receiv
dental
evalu
relev
treatment
condit
therapi
begin
aiii
like
sourc
dental
infect
vigor
elimin
aiii
exampl
teeth
moder
sever
cari
restor
illfit
dental
prosthes
repair
teeth
compromis
moder
sever
periodont
diseas
extract
ideal
day
elaps
complet
tissueinvas
oral
procedur
onset
condit
therapi
allow
adequ
heal
monitor
postsurg
complic
aiii
hsct
recipi
mucos
hsct
candid
undergo
condit
therapi
maintain
safe
oral
hygien
perform
oral
rins
timesday
steril
water
normal
salin
sodium
bicarbon
solut
aiii
hsct
recipi
candid
brush
teeth
timesday
soft
regular
toothbrush
biii
recipi
toler
brush
use
ultrasoft
toothbrush
toothett
ie
foam
swab
stick
use
ciii
physician
awar
use
latter
product
less
desir
use
soft
regular
ultrasoft
toothbrush
toothett
remov
less
dental
debri
use
toothpast
option
depend
recipi
toler
ciii
hsct
recipi
candid
undergo
condit
therapi
skill
dental
floss
floss
daili
done
without
trauma
biii
routin
dental
supervis
advis
monitor
guid
patient
mainten
oral
dental
hygien
biii
decreas
risk
mechan
trauma
infect
oral
mucosa
fix
orthodont
applianc
space
maintain
worn
start
condit
therapi
preengraft
mucos
resolv
devic
worn
subsequ
period
mucos
diii
dental
transplant
team
patient
commun
dentist
coordin
remov
applianc
longterm
rehabilit
oral
lesion
biii
howev
patient
normal
wear
remov
dental
prosthes
might
abl
wear
condit
therapi
hsct
mucos
hsct
depend
degre
tissu
integr
denturebear
site
abil
patient
maintain
dentur
hygien
daili
basi
ciii
hsct
center
personnel
advis
implement
publish
guidelin
prevent
intravascular
devicerel
infect
aiii
contact
tap
water
central
venou
cathet
site
avoid
biii
longterm
central
venou
access
among
children
hsct
physician
use
total
implant
devic
among
children
age
year
anticip
durat
vascular
access
day
cii
howev
devic
among
children
age
year
gener
use
actual
hsct
infus
site
problem
skin
fragil
contraind
repeat
punctur
port
site
b
port
devic
might
insuffici
number
lumen
optim
patient
manag
immedi
hsct
prevent
bloodstream
infect
associ
needleless
intraven
access
devic
hsct
recipi
cover
protect
cathet
tip
end
cap
bath
shower
protect
tap
water
contamin
b
chang
devic
accord
manufactur
recommend
avail
c
caregiv
perform
intraven
infus
whenev
possibl
bii
also
hsct
recipi
caregiv
educ
regard
proper
care
needleless
intraven
access
devic
bii
recommend
regard
use
antibiot
impregn
central
venou
cathet
among
hsct
recipi
made
lack
data
hsct
physician
alway
includ
legionnair
diseas
ld
differenti
diagnosi
pneumonia
among
hsct
recipi
aiii
appropri
test
confirm
ld
includ
cultur
sputum
bal
tissu
specimen
b
test
bal
specimen
legionella
direct
fluoresc
antibodi
c
test
legionella
pneumophila
serogroup
antigen
urin
incub
period
ld
usual
day
thu
laboratoryconfirm
legionellosi
occur
patient
hospit
continu
day
onset
ill
regard
definit
case
nosocomi
ld
laboratoryconfirm
infect
occur
day
hospit
admiss
possibl
case
nosocomi
ld
case
laboratori
confirm
nosocomi
ld
identifi
person
inpati
hsct
center
part
day
ill
onset
two
case
laboratoryconfirm
ld
occur
among
patient
visit
outpati
hsct
center
hospit
personnel
report
case
local
state
health
depart
diseas
report
state
assist
need
aiii
consult
hospit
infect
control
team
conduct
thorough
epidemiolog
environment
investig
determin
like
environment
sourc
legionella
speci
eg
shower
tap
water
faucet
cool
tower
hot
water
tank
ai
sourc
legionella
infect
identifi
decontamin
remov
aiii
extens
hospit
investig
isol
case
possibl
nosocomi
ld
might
indic
patient
limit
contact
inpati
center
incub
period
ciii
hsct
recipi
much
higher
risk
diseas
death
legionellosi
compar
hospit
person
period
routin
cultur
legionella
water
sampl
center
potabl
water
suppli
could
regard
part
overal
strategi
prevent
ld
hsct
center
ciii
howev
optim
methodolog
ie
frequenc
number
site
environment
surveil
cultur
hsct
center
determin
costeffect
strategi
evalu
hsct
recipi
high
risk
ld
data
found
determin
safe
concentr
legionella
organ
potabl
water
goal
environment
surveil
legionella
undertaken
maintain
water
system
detect
organ
aiii
physician
suspect
legionellosi
among
hsct
recipi
nosocomi
pneumonia
even
environment
surveil
cultur
yield
legionella
aiii
legionella
speci
detect
water
suppli
hsct
center
follow
done
legionella
speci
longer
detect
cultur
water
suppli
decontamin
aii
hsct
recipi
given
spong
bath
water
contamin
legionella
speci
eg
hsct
center
legionella
speciescontamin
potabl
water
system
biii
patient
take
shower
ldcontamin
water
diii
water
faucet
contain
ldcontamin
water
use
patient
room
hsct
center
outpati
clinic
avoid
creat
infecti
aerosol
ciii
hsct
recipi
given
steril
water
instead
tap
water
drink
brush
teeth
flush
nasogastr
tube
legionellosi
outbreak
biii
hsct
center
personnel
use
steril
water
ie
distil
unsteril
water
rins
nebul
devic
semicrit
respiratorycar
equip
clean
disinfect
fill
reservoir
nebul
devic
bii
hsct
center
use
largevolum
room
air
humidifi
creat
aerosol
eg
venturi
principl
ultrasound
spin
disk
thu
actual
nebul
di
unless
humidifi
nebul
steril
subject
daili
highlevel
disinfect
fill
steril
water
ciii
new
hospit
hsct
center
construct
cool
tower
place
tower
drift
direct
away
hospit
airintak
system
cool
tower
design
volum
aerosol
drift
minim
sta
aureu
hsct
center
hcw
follow
basic
infect
control
practic
eg
hand
wash
patient
use
barrier
precaut
includ
wear
glove
whenev
enter
methicillinresist
sta
aureu
mrsa
infect
colon
patient
room
practic
essenti
mrsa
control
aii
mrsa
substanti
problem
hsct
center
evid
exist
ongo
mrsa
transmiss
mrsa
infect
colon
patient
treat
cohort
eg
care
exclus
limit
number
hcw
biii
hsct
transplant
recipi
recurr
sta
aureu
infect
undergo
extens
evalu
persist
colon
includ
cultur
nare
groin
axilla
ostomi
site
eg
tracheostomi
gastrointestin
tube
biii
patient
recurr
mrsa
infect
elimin
carrier
state
attempt
appli
mupirocin
calcium
ointment
nare
biii
although
strategi
margin
effect
certain
institut
appendix
highlevel
mupirocinresist
mrsa
report
europ
middl
east
south
america
uncommon
unit
state
antibiot
incorrect
overus
mupirocin
result
mupirocinresist
staphylococci
therefor
mupirocin
use
reserv
infect
control
strategi
patient
fail
mupirocin
physician
use
bacitracin
tmpsmz
rifampin
administ
anoth
antibiot
standard
protocol
use
drug
indic
evalu
recommend
made
lack
data
select
system
antibiot
guid
suscept
pattern
intravascular
cannula
implant
devic
infect
colon
mrsa
remov
aiii
patient
mrsa
place
contact
precaut
antibiot
discontinu
three
consecut
cultur
taken
week
apart
neg
biii
screen
cultur
mrsa
includ
anterior
nare
bodi
site
previous
posit
mrsa
wound
surgic
site
hsct
center
suffici
laboratori
capabl
identifi
staphylococci
isol
suscept
pattern
antibiot
includ
vancomycin
avoid
overus
misus
antibiot
decreas
emerg
staphylococcu
speci
reduc
suscept
vancomycin
therefor
medic
ancillari
staff
member
respons
monitor
antimicrobi
use
pattern
facil
routin
review
vancomycinus
pattern
use
intraven
vancomycin
associ
vre
emerg
vancomycin
antibiot
particularli
antianaerob
agent
eg
metronidazol
thirdgener
cephalosporin
must
use
judici
wash
hand
antibacteri
soap
enter
leav
hsct
recipi
room
particularli
vre
colon
infect
altern
wash
hand
waterless
antisept
agent
eg
alcoholbas
rins
gel
whenev
possibl
treat
cohort
patient
known
colon
infect
vre
disinfect
patient
room
equip
includ
surfac
hospit
ward
environ
eg
floor
wall
bed
frame
door
bathroom
surfac
fdaor
eparegist
disinfect
hsct
physician
follow
publish
recommend
prevent
control
cl
difficil
diseas
includ
minim
durat
antibiot
therapi
number
antibiot
use
indic
aiii
patient
cl
difficil
diseas
place
contact
precaut
durat
ill
aii
hcw
anticip
contact
cl
difficil
infect
patient
patient
environ
possess
put
glove
enter
patient
room
handl
patient
secret
excret
ai
cl
difficil
outbreak
hsct
center
personnel
restrict
use
antibiot
eg
clindamycin
bii
prevent
transmiss
cl
difficil
patient
nosocomi
cl
difficil
outbreak
hsct
center
hcw
use
dispos
rectal
thermomet
tympan
thermomet
b
disinfect
gastrointestin
endoscop
glutaraldehyd
immers
minut
use
equival
disinfect
strategi
c
perform
surfac
steril
hospit
ward
environ
eg
floor
wall
bed
frame
door
bathroom
surfac
fdaor
eparegist
steril
eg
phosphatebuff
sodium
hypochlorit
solut
ppm
avail
chlorid
unbuff
hypochlorit
solut
ppm
avail
chlorid
formaldehyd
glutaraldehyd
ethylen
oxid
bii
addit
physician
treat
patient
cl
difficil
diseas
antibiot
recommend
publish
report
bii
certain
research
also
recommend
antibiot
treatment
cl
difficil
carrier
howev
research
report
treatment
asymptomat
cl
difficil
carrier
metronidazol
effect
treatment
vancomycin
effect
temporarili
ie
month
treatment
consequ
recommend
regard
treatment
asymptomat
cl
difficil
carrier
made
similarli
although
symptomat
cl
difficil
diseas
recurr
relaps
occur
among
patient
data
insuffici
make
recommend
prevent
multipl
cl
difficil
relaps
follow
practic
recommend
cl
difficil
control
routin
stool
surveil
cultur
cl
difficil
asymptomat
patient
hcw
even
outbreak
diii
cultur
hcw
hand
cl
difficil
diii
treat
patient
presumpt
cl
difficil
diseas
pend
toxin
result
diii
unless
patient
sick
compat
syndrom
hospit
high
preval
cl
difficil
ciii
prophylact
use
lyophil
saccharomyc
boulardii
reduc
diarrhea
among
antibiot
recipi
recommend
therapi
associ
substanti
reduct
diarrhea
associ
cl
difficil
diseas
associ
saccharomyc
boulardii
fungemia
dii
physician
institut
appropri
precaut
infect
control
measur
prevent
nosocomi
pneumonia
among
hospit
hsct
recipi
candid
undergo
condit
therapi
particularli
commun
nosocomi
crv
outbreak
aiii
patient
uri
lri
symptom
place
contact
precaut
viral
respiratori
infect
includ
varicella
b
droplet
precaut
influenza
adenoviru
c
airborn
precaut
measl
varicella
avoid
transmit
infect
hsct
candid
recipi
well
hcw
visitor
biii
identifi
hsct
recipi
rsv
infect
place
contact
precaut
immedi
aiii
prevent
nosocomi
transmiss
critic
suction
respiratori
tract
patient
uri
lri
symptom
hcw
wear
gown
surgic
mask
eye
protect
avoid
contamin
patient
respiratori
secret
protect
cloth
eg
gown
glove
surgic
mask
eye
protect
put
enter
patient
room
discard
room
exit
protect
cloth
alway
chang
patient
room
aiii
care
hsct
recipi
candid
undergo
condit
therapi
uri
lri
hcw
visitor
chang
glove
wash
hand
contact
patient
b
handl
respiratori
secret
object
contamin
secret
one
patient
contact
anoth
patient
object
environment
surfac
c
contact
contamin
bodi
site
respiratori
tract
respiratori
devic
use
patient
aii
practic
critic
respiratori
infect
usual
transmit
contact
particularli
hand
nose
eye
therefor
wear
mask
without
appropri
hand
wash
glovewear
use
eye
protect
insuffici
prevent
transmiss
crv
infect
research
propos
hsct
recipi
candid
undergo
condit
therapi
place
contact
precaut
nosocomi
outbreak
ciii
even
nosocomi
commun
outbreak
crv
infect
exist
person
enter
hsct
center
screen
daili
uri
symptom
includ
visitor
hcw
biii
research
also
describ
system
hcw
provid
daili
verif
eg
use
signin
sheet
free
uri
symptom
allow
provid
hsct
patient
care
hcw
visitor
uri
symptom
restrict
contact
hsct
recipi
candid
undergo
condit
therapi
minim
risk
crv
transmiss
aiii
hcw
uri
symptom
restrict
patient
contact
reassign
nonpati
care
duti
hcw
symptom
resolv
biii
visitor
uri
symptom
ask
defer
visit
hsct
center
uri
symptom
resolv
biii
respiratori
secret
hospit
hsct
candid
recipi
sign
symptom
crv
infect
test
promptli
viral
cultur
rapid
diagnost
test
crv
biii
appropri
sampl
includ
nasopharyng
wash
swab
aspir
throat
swab
bal
fluid
practic
critic
preemptiv
treatment
certain
crv
eg
influenza
rsv
might
prevent
sever
diseas
death
among
hsct
recipi
viral
shed
among
hsct
recipi
crv
infect
report
last
month
influenza
year
adenoviru
day
rsv
howev
rsv
viral
shed
report
last
day
child
sever
combin
immunodefici
therefor
prevent
nosocomi
transmiss
crv
hsct
center
hcw
recogn
prolong
crv
shed
occur
determin
durat
appropri
precaut
crvinfect
hsct
recipi
candid
undergo
condit
therapi
ciii
hsct
center
use
serial
test
use
cultur
nasopharyng
swab
throat
swab
aspir
rapid
antigen
test
help
determin
whether
patient
stop
shed
influenza
viru
biii
research
propos
hsct
physician
conduct
routin
crv
surveil
among
hsct
recipi
detect
outbreak
implement
infect
control
measur
earli
possibl
ciii
rsv
season
hsct
recipi
candid
sign
symptom
test
rsv
infect
ie
presenc
rsv
antigen
respiratori
secret
test
enzymelink
immunosorb
assay
viral
cultur
start
admiss
hsct
center
patient
rsvantigen
posit
treat
cohort
nosocomi
rsv
outbreak
practic
reduc
nosocomi
rsv
transmiss
bii
symptomat
hcw
exclud
patient
contact
symptom
resolv
hcw
visitor
infecti
conjunct
restrict
direct
patient
contact
drainag
resolv
ie
usual
day
adenoviru
ophthalmolog
consult
concur
infect
inflamm
resolv
aii
avoid
possibl
transmiss
adenoviru
hsct
recipi
prevent
crv
exposur
among
hsct
recipi
hospit
discharg
challeng
high
crv
preval
prevent
measur
individu
accord
immunolog
statu
toler
patient
outpati
wait
room
patient
crv
infect
separ
extent
possibl
patient
biii
hsct
candid
screen
tb
care
medic
histori
chart
review
ascertain
histori
prior
tb
exposur
aiii
immunocompromis
person
higher
risk
progress
latent
tb
infect
activ
diseas
also
physician
administ
tuberculin
skin
test
tst
use
mantoux
method
five
tuberculin
unit
purifi
protein
deriv
ciii
patient
immunocompromis
test
might
reliabl
tst
administ
either
tubersol
aplisol
formul
purifi
protein
deriv
use
person
recent
posit
tst
histori
posit
tst
prior
prevent
therapi
administ
chest
radiograph
evalu
activ
tb
ai
immunocompromis
person
posit
tst
defin
mm
indur
decreas
abil
mount
delay
hypersensit
respons
ciii
immunosuppress
therapi
decreas
sensit
tst
hsct
physician
reli
sole
tst
determin
whether
latent
tb
infect
present
whether
prevent
therapi
administ
hsct
recipi
candid
diii
instead
full
cours
isonicotin
acid
hydrazid
prevent
therapi
administ
immunocompromis
hsct
recipi
candid
substanti
expos
someon
activ
infecti
ie
sputumsmear
posit
pulmonari
laryng
tb
regardless
hsct
recipi
candid
tst
statu
biii
full
cours
isonicotin
acid
hydrazid
prevent
therapi
also
administ
hsct
recipi
candid
posit
tst
previous
treat
evid
activ
tb
diseas
aiii
appendix
routin
anergi
screen
might
reliabl
among
hsct
recipi
candid
undergo
condit
therapi
therefor
recommend
diii
hsct
cancel
delay
posit
tst
diii
use
cours
daili
pyrazinamiderifampin
pzarif
regimen
recommend
altern
prevent
therapi
person
tb
howev
limit
data
found
regard
safeti
efficaci
regimen
among
nonhivinfect
person
furthermor
rifampin
substanti
drug
interact
certain
medic
includ
cyclosporin
tacrolimu
corticosteroid
fluconazol
pain
medic
therefor
routin
use
pzarif
prophylact
regimen
among
hsct
recipi
recommend
diii
howev
regimen
use
hsct
candid
risk
seriou
rifampin
drug
interact
whose
hsct
schedul
week
complet
pzarif
cours
ciii
delay
diminish
possibl
advers
effect
rifampin
drug
use
routin
hsct
oi
prophylaxi
eg
fluconazol
hsct
candid
recipi
expos
activ
case
extrapulmonari
therefor
noninfecti
tb
requir
prevent
therapi
diii
hsct
center
personnel
follow
guidelin
regard
control
tb
healthcar
facil
includ
institut
airborn
precaut
neg
pressur
room
patient
suspect
confirm
pulmonari
laryng
tb
aii
hcw
wear
respir
even
isol
room
protect
possibl
tb
transmiss
patient
activ
pulmonari
laryng
tb
particularli
coughinduc
procedur
aiii
maxim
effect
respir
eg
must
fittest
respir
user
must
train
use
correctli
aiii
unless
becom
soil
damag
chang
respir
patient
room
necessari
diii
bacillu
calmett
vaccin
contraind
among
hsct
candid
recipi
might
caus
dissemin
fatal
diseas
among
immunocompromis
person
eii
role
identifi
chronic
suppress
therapi
followup
surveil
cultur
among
hsct
recipi
histori
success
treat
tb
diii
hsct
center
personnel
advis
follow
standard
guidelin
surveil
antimicrobi
use
nosocomi
pathogen
suscept
pattern
biii
hsct
center
personnel
perform
routin
fungal
bacteri
cultur
asymptomat
hsct
recipi
dii
absenc
epidemiolog
cluster
infect
hsct
center
personnel
perform
routin
period
bacteri
surveil
cultur
hsct
center
environ
equip
devic
use
respiratori
therapi
pulmonaryfunct
test
deliveri
inhal
anesthesia
diii
research
recommend
hospit
perform
routin
sampl
air
ceil
tile
ventil
duct
filter
test
mold
particularli
construct
renov
occur
near
around
room
immunocompromis
patient
clinic
surveil
demonstr
possibl
increas
mold
ie
aspergillosi
case
ciii
strategi
might
decreas
fungal
spore
ventil
system
includ
elimin
access
bird
ie
primarili
pigeon
airintak
system
remov
bird
drop
airintak
duct
elimin
moss
hospit
roof
furthermor
absenc
nosocomi
fungal
outbreak
hsct
center
need
perform
routin
fungal
cultur
devic
dust
room
hsct
recipi
candid
undergo
condit
therapi
diii
hsct
center
personnel
routin
perform
surveil
number
aspergillosi
case
occur
among
hsct
recipi
particularli
hospit
construct
renov
biii
twofold
greater
increas
attack
rate
aspergillosi
period
indic
hsct
center
environ
evalu
break
infect
control
techniqu
procedur
ventil
system
investig
care
biii
hsct
recipi
candid
undergo
condit
therapi
particularli
allogen
recipi
parent
pediatr
hsct
recipi
candid
educ
regard
strategi
avoid
environment
exposur
opportunist
pathogen
aiii
hsct
recipi
candid
wash
hand
thoroughli
ie
soap
water
often
exampl
hand
wash
eat
prepar
food
chang
diaper
garden
touch
plant
dirt
touch
pet
anim
touch
secret
excret
item
might
contact
human
anim
stool
eg
cloth
bed
toilet
bedpan
go
outdoor
touch
wound
aiii
conscienti
hand
wash
critic
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
aiii
pediatr
hsct
recipi
candid
supervis
adult
hand
wash
ensur
thorough
clean
biii
hand
wash
perform
antimicrobi
soap
water
aiii
altern
use
hygien
hand
rub
accept
mean
maintain
hand
hygien
hsct
recipi
visit
live
farm
follow
publish
recommend
prevent
cryptosporidiosi
biii
prevent
respiratori
infect
hospit
discharg
hsct
recipi
observ
follow
precaut
frequent
thorough
hand
wash
critic
biii
hsct
recipi
also
avoid
touch
mucu
membran
unless
wash
hand
first
avoid
inocul
crv
hsct
recipi
avoid
close
contact
person
respiratori
ill
biii
close
contact
unavoid
person
respiratori
ill
encourag
wash
hand
frequent
wear
surgic
mask
minimum
smother
sneez
cough
dispos
tissu
altern
hsct
recipi
wear
surgic
mask
ciii
hsct
recipi
avoid
crowd
area
eg
shop
mall
public
elev
close
contact
person
respiratori
ill
like
biii
hsct
candid
recipi
advis
certain
activ
occup
eg
work
healthcar
set
prison
jail
homeless
shelter
increas
risk
tb
exposur
biii
decid
whether
patient
continu
activ
set
physician
evalu
patient
specif
duti
precaut
use
prevent
tb
exposur
workplac
preval
tb
commun
decis
continu
termin
activ
made
jointli
patient
physician
biii
hsct
recipi
avoid
exposur
person
activ
tuberculosi
particularli
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
biii
research
report
allogen
recipi
avoid
construct
excav
site
dustladen
environ
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
avoid
exposur
mold
ciii
research
also
report
outpati
hsct
recipi
advis
travel
rout
hsct
center
avoid
minim
exposur
construct
site
ciii
coccidioidomycosi
uncommon
allogen
hsct
howev
research
report
hsct
recipi
travel
resid
coccidioidomycosisendem
area
eg
american
southwest
mexico
central
south
america
avoid
minim
exposur
disturb
soil
includ
construct
excav
site
area
recent
earthquak
farm
rural
area
ciii
histoplasmosi
histoplasma
capsulatum
allogen
hsct
also
rare
howev
research
report
hsct
recipi
histoplasmosisendem
area
avoid
exposur
chicken
coop
birdroost
site
cave
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
ciii
smoke
tobacco
exposur
environment
tobacco
smoke
risk
factor
bacteri
crv
infect
among
healthi
adult
children
consequ
logic
dictat
physician
advis
hsct
recipi
smoke
avoid
exposur
environment
tobacco
smoke
ciii
howev
data
found
specif
assess
whether
smoke
environment
smoke
exposur
risk
factor
oi
among
hsct
recipi
research
report
marijuana
smoke
might
associ
gener
invas
pulmonari
aspergillosi
among
immunocompromis
person
includ
hsct
recipi
therefor
hsct
recipi
refrain
smoke
marijuana
avoid
aspergillu
speci
exposur
biii
research
propos
immunocompromis
hsct
recipi
candid
undergo
condit
therapi
avoid
garden
direct
contact
soil
plant
aerosol
reduc
exposur
potenti
pathogen
eg
gondii
hi
capsulatum
cryptococcu
neoforman
nocardia
speci
aspergillu
speci
ciii
hsct
recipi
particularli
allogen
recipi
could
wear
glove
garden
touch
plant
soil
ciii
avoid
creat
plant
soil
aerosol
biii
addit
alway
wash
hand
afterward
care
skin
abras
cut
sustain
soil
plant
contact
aiii
person
whose
occup
involv
anim
contact
eg
veterinarian
pet
store
employe
farmer
slaughterhous
worker
could
increas
risk
toxoplasmosi
zoonot
diseas
although
data
insuffici
justifi
gener
recommend
hsct
recipi
work
set
exposur
avoid
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
biii
sexual
activ
hsct
recipi
avoid
sexual
practic
could
result
oral
exposur
fece
aiii
sexual
activ
patient
longterm
monogam
relationship
alway
use
latex
condom
sexual
contact
reduc
risk
exposur
cmv
hsv
hiv
hepat
b
c
sexual
transmit
pathogen
aii
howev
even
longtim
monogam
partner
discord
infect
therefor
period
immunocompromis
sexual
activ
hsct
recipi
relationship
consid
use
latex
condom
sexual
contact
reduc
risk
exposur
sexual
transmit
infect
ciii
hsct
physician
advis
recipi
candid
undergo
condit
therapi
potenti
infect
risk
pose
pet
ownership
howev
routin
advis
hsct
recipi
part
pet
limit
except
gener
immunocompromis
hsct
recipi
candid
undergo
condit
therapi
minim
direct
contact
anim
particularli
anim
ill
eg
diarrhea
biii
immunocompromis
person
choos
pet
vigil
regard
mainten
pet
health
immunocompet
pet
owner
biii
recommend
mean
seek
veterinari
care
pet
earli
pet
ill
minim
possibl
transmiss
pet
ill
owner
biii
feed
pet
highqual
commerci
pet
food
reduc
possibl
ill
caus
spoil
contamin
food
thu
reduc
possibl
transmit
ill
pet
hsct
recipi
egg
poultri
meat
product
given
pet
supplement
wellcook
dairi
product
given
pet
pasteur
biii
pet
prevent
drink
toilet
bowl
water
access
garbag
pet
scaveng
hunt
eat
anim
fece
biii
hsct
recipi
contact
pet
anim
wash
hand
handl
particularli
eat
clean
cage
hsct
recipi
avoid
contact
anim
fece
reduc
risk
toxoplasmosi
cryptosporidiosi
salmonellosi
campylobacteriosi
biii
adult
supervis
hand
wash
pediatr
hsct
recipi
biii
immunocompromis
hsct
recipi
candid
clean
pet
litter
box
cage
dispos
anim
wast
diii
avoid
patient
wear
dispos
glove
activ
wash
hand
thoroughli
afterward
biii
immunocompromis
hsct
recipi
candid
avoid
adopt
ill
juvenil
pet
eg
age
month
cat
stray
anim
biii
pet
experi
diarrhea
check
veterinarian
infect
cryptosporidium
giardia
speci
salmonella
campylobact
biii
immunocompromis
hsct
recipi
candid
contact
reptil
eg
snake
lizard
turtl
iguana
dii
reduc
risk
acquir
salmonellosi
addit
patient
inform
salmonellosi
occur
fomit
contact
alon
therefor
hsct
recipi
candid
avoid
contact
reptil
food
anyth
touch
contact
occur
recipi
candid
wash
hand
thoroughli
afterward
aiii
immunocompromis
hsct
recipi
candid
avoid
contact
duckl
chick
risk
acquir
salmonella
campylobact
speci
infect
biii
immunocompromis
hsct
recipi
candid
avoid
contact
exot
pet
eg
nonhuman
primat
biii
bird
cage
line
clean
regularli
eg
daili
person
particularli
immunocompromis
hsct
candid
recipi
wear
glove
whenev
handl
item
contamin
bird
drop
biii
drop
sourc
cryptococcu
neoforman
mycobacterium
avium
hi
capsulatum
howev
routin
screen
healthi
bird
diseas
recommend
diii
minim
potenti
exposur
mycobacterium
marinum
immunocompromis
hsct
recipi
candid
clean
fish
tank
diii
task
avoid
patient
wear
dispos
glove
activ
wash
hand
thoroughli
afterward
biii
major
toxoplasmosi
case
unit
state
acquir
eat
undercook
meat
howev
hsct
recipi
candid
particularli
gondii
seroneg
inform
risk
contract
toxoplasmosi
cat
fece
biii
need
advis
give
away
cat
dii
household
cat
litter
box
place
kitchen
dine
room
area
food
prepar
eat
occur
addit
litter
box
clean
daili
someon
hsct
recipi
first
month
hsct
period
substanti
immunosuppress
eg
gvhd
steroid
use
relaps
underli
diseas
transplant
perform
reduc
risk
transmit
toxoplasmosi
hsct
recipi
biii
daili
litter
box
chang
minim
risk
fecal
transmiss
gondii
oocyst
fecal
oocyst
requir
day
incub
becom
infecti
hsct
recipi
perform
task
first
month
hsct
subsequ
period
substanti
immunocompromis
eg
gvhd
system
steroid
use
relaps
underli
neoplast
diseas
transplant
perform
wear
dispos
glove
glove
discard
singl
use
biii
soil
dri
litter
dispos
care
prevent
aerosol
gondii
oocyst
biii
cat
fece
litter
flush
toilet
biii
also
person
clean
cat
litter
particularli
hsct
recipi
wash
hand
thoroughli
soap
water
afterward
reduc
risk
acquir
toxoplasmosi
biii
hsct
recipi
candid
cat
keep
cat
insid
biii
adopt
handl
stray
cat
diii
cat
fed
can
dri
commerci
food
wellcook
tabl
food
raw
undercook
meat
elimin
possibl
caus
ill
could
transmit
cat
hsct
recipi
biii
pet
cat
hsct
recipi
need
test
toxoplasmosi
eii
playground
sandbox
kept
cover
use
prevent
cat
soil
biii
hsct
recipi
candid
undergo
condit
therapi
avoid
drink
ing
raw
goat
milk
decreas
risk
acquir
toxoplasmosi
biii
although
limit
data
found
regard
risk
epidemiolog
cryptosporidium
diseas
among
hsct
recipi
hsct
recipi
prudent
avoid
possibl
exposur
cryptosporidium
biii
report
caus
sever
chronic
diarrhea
malnutrit
death
among
immunocompromis
person
hsct
recipi
avoid
walk
wade
swim
play
recreat
water
eg
pond
lake
like
contamin
cryptosporidium
es
coli
sewag
anim
human
wast
bii
hsct
recipi
also
avoid
swallow
water
eg
swim
well
water
taken
directli
river
lake
aiii
hsct
recipi
use
well
water
privat
well
public
well
commun
limit
popul
diii
test
microbi
contamin
perform
infrequ
eg
certain
locat
test
perform
timesmonth
detect
sporad
bacteri
contamin
howev
drink
well
water
municip
well
serv
highli
popul
area
regard
safe
bacteri
contamin
water
test
timesday
bacteri
contamin
hsct
recipi
consum
tap
water
routin
monitor
mass
media
eg
radio
televis
newspap
area
immedi
implement
boilwat
advisori
might
issu
immunocompromis
person
state
local
govern
biii
boilwat
advisori
mean
tap
water
boil
minut
consum
tap
water
might
complet
free
cryptosporidium
elimin
risk
cryptosporidium
exposur
tap
water
hsct
recipi
boil
tap
water
minut
consum
eg
drink
brush
teeth
ciii
altern
use
certain
type
water
filter
home
distil
reduc
risk
cryptosporidium
waterborn
pathogen
ciii
home
water
filter
use
capabl
remov
particl
diamet
filter
revers
osmosi
howev
major
filter
capabl
remov
smaller
microb
eg
bacteria
virus
therefor
use
properli
treat
municip
water
major
devic
would
appropri
use
unchlorin
privat
well
control
viral
bacteri
pathogen
bottl
water
consum
process
remov
cryptosporidium
one
three
process
revers
osmosi
distil
particul
absolut
filtrat
confirm
specif
bottl
water
undergon
one
process
hsct
recipi
contact
bottler
directli
patient
take
precaut
absenc
boilwat
advisori
reduc
risk
cryptosporidiosi
extra
precaut
includ
avoid
fountain
beverag
ice
made
tap
water
restaur
bar
theater
fruit
drink
made
frozen
concentr
mix
tap
water
ice
tea
coffe
made
tap
water
drink
like
cryptosporidium
safe
hsct
recipi
includ
nation
distribut
brand
bottl
can
carbon
soft
drink
beer
commerci
packag
noncarbon
drink
contain
fruit
juic
fruit
juic
requir
refriger
open
eg
store
unrefriger
groceri
shelv
can
bottl
soda
seltzer
fruit
drink
steam
hot
f
tea
coffe
juic
label
pasteur
nation
distribut
brand
frozen
fruit
juic
concentr
reconstitut
water
safe
sourc
hsct
recipi
drink
unpasteur
milk
fruit
veget
juic
eg
appl
cider
orang
juic
avoid
infect
brucella
speci
es
coli
salmonella
speci
cryptosporidium
other
dii
hsct
candid
household
famili
member
prepar
food
hsct
review
food
safeti
practic
appropri
person
aiii
food
prepar
educ
regard
addit
food
safeti
practic
appropri
hsct
recipi
review
educ
done
condit
regimen
ie
chemotherapi
radiat
begin
biii
adher
guidelin
decreas
risk
foodborn
diseas
among
hsct
recipi
raw
poultri
meat
fish
seafood
handl
separ
surfac
eg
cut
board
counter
top
food
item
food
prepar
alway
use
separ
cut
board
ie
one
poultri
meat
one
veget
remain
cut
carv
task
aiii
board
wash
warm
water
soap
cut
differ
food
item
aiii
prevent
foodborn
ill
caus
campylobact
jejuni
salmonella
enteritidi
caus
sever
invas
infect
among
immunocompromis
person
uncook
meat
come
contact
food
biii
prepar
raw
poultri
meat
fish
seafood
prepar
food
food
handler
wash
hand
thoroughli
warm
soapi
water
cut
board
counter
knive
utensil
use
wash
thoroughli
warm
soapi
water
also
aiii
food
prepar
keep
shelv
counter
top
refriger
freezer
utensil
spong
towel
kitchen
item
clean
aiii
fresh
produc
wash
thoroughli
run
water
serv
aiii
person
prepar
food
follow
publish
us
depart
agricultur
recommend
regard
safe
food
thaw
biii
person
cook
food
hsct
recipi
follow
establish
guidelin
monitor
intern
cook
temperatur
meat
aii
method
determin
whether
meat
adequ
cook
measur
intern
temperatur
thermomet
color
meat
cook
reliabl
reflect
intern
temperatur
differ
kind
meat
cook
vari
intern
temperatur
f
aii
specif
us
depart
agricultur
recommend
poultri
cook
intern
temperatur
f
meat
eggcontain
casserol
souffl
cook
intern
temperatur
f
cold
food
store
f
hot
food
kept
f
biii
food
prepar
wash
hand
handl
leftov
aiii
use
clean
utensil
foodprepar
surfac
aiii
divid
leftov
small
unit
store
shallow
contain
quick
cool
aii
refriger
leftov
within
hour
cook
aii
discard
leftov
kept
room
temperatur
hour
aiii
reheat
leftov
heat
partial
cook
food
f
throughout
serv
aii
bring
leftov
soup
sauc
gravi
roll
boil
serv
aiii
follow
publish
guidelin
cold
storag
food
aii
hsct
recipi
diet
restrict
decreas
risk
exposur
foodborn
infect
bacteria
yeast
mold
virus
parasit
biii
current
low
microbi
diet
recommend
hsct
recipi
biii
diet
continu
month
hsct
autolog
recipi
allogen
recipi
remain
diet
immunosuppress
drug
eg
cyclosporin
steroid
tacrolimu
discontinu
howev
hsct
physician
final
respons
determin
diet
discontinu
safe
one
studi
report
dietari
chang
eg
consum
yogurt
decreas
risk
mycot
infect
eg
candid
vagin
tabl
hsct
recipi
eat
raw
undercook
meat
includ
beef
poultri
pork
lamb
venison
wild
game
combin
dish
contain
raw
undercook
meat
sweetbread
anim
eg
sausag
casserol
aii
also
hsct
recipi
consum
raw
undercook
egg
food
might
contain
eg
certain
prepar
hollandais
sauc
caesar
salad
dress
homemad
mayonnais
homemad
eggnog
risk
infect
salmonella
enteritidi
aii
hsct
recipi
consum
raw
undercook
seafood
eg
oyster
clam
prevent
exposur
vibrio
speci
viral
gastroenter
cryptosporidium
parvum
aii
hsct
recipi
candid
consum
meat
welldon
caretak
direct
control
food
prepar
eg
eat
restaur
ai
date
evid
exist
unit
state
eat
food
fast
food
restaur
riskier
eat
convent
sitdown
restaur
gener
hsct
candid
undergo
condit
therapi
hsct
recipi
neutropenia
ie
anc
gvhd
immunosuppress
avoid
exposur
naturopath
medicin
might
contain
mold
diii
hsct
recipi
wish
take
naturopath
medic
advis
use
prescrib
licens
naturopath
physician
work
consult
recipi
transplant
infecti
diseas
physician
ciii
travel
develop
countri
pose
substanti
risk
exposur
opportunist
pathogen
hsct
recipi
particularli
allogen
recipi
chronic
immunosuppress
hsct
recipi
plan
travel
develop
countri
without
consult
physician
aiii
travel
occur
period
sever
immunosuppress
resolv
gener
allogen
recipi
plan
travel
develop
countri
month
hsct
particularli
gvhd
occur
autolog
recipi
travel
develop
countri
month
hsct
physician
agre
hsct
recipi
inform
regard
strategi
minim
risk
acquir
foodborn
waterborn
infect
travel
obtain
updat
detail
health
inform
intern
travel
health
organ
aiii
gener
travel
develop
countri
hsct
recipi
avoid
consum
follow
biii
raw
fruit
veget
tap
water
potenti
untreat
contamin
water
ice
made
tap
water
potenti
contamin
water
unpasteur
milk
unpasteur
dairi
product
fresh
fruit
juic
food
drink
street
vendor
raw
undercook
egg
steam
hot
food
fruit
peel
oneself
bottl
can
process
drink
hot
coffe
tea
probabl
safe
travel
plan
treat
drink
water
develop
countri
bottl
water
avail
boil
best
method
make
water
safe
howev
boil
water
feasibl
travel
carri
suppli
disinfect
water
eg
commerci
avail
iodin
disinfect
tablet
portabl
water
filter
antimicrobi
prophylaxi
travel
diarrhea
recommend
routin
hsct
recipi
travel
develop
countri
diii
travel
diarrhea
known
frequent
sever
among
immunocompromis
host
howev
hsct
physician
wish
provid
prophylaxi
hsct
recipi
travel
prescrib
fluoroquinolon
eg
ciprofloxacin
hydrochlorid
tmpsmz
ciii
although
resist
tmpsmz
common
resist
fluoroquinolon
increas
tropic
area
appendix
research
recommend
use
bismuth
subsalicyl
prevent
travel
diarrhea
among
adult
howev
data
found
regard
safeti
efficaci
among
hsct
recipi
salicyl
recommend
use
among
person
age
year
salicyl
associ
rey
syndrom
hsct
recipi
immun
statu
assess
vaccin
updat
need
travel
influenza
chemoprophylaxi
rimantadin
amantadin
use
immunocompromis
hsct
recipi
travel
outsid
continent
unit
state
could
expos
influenza
ciii
antibodi
titer
vaccineprevent
diseas
eg
tetanu
polio
measl
mump
rubella
encapsul
organ
declin
year
allogen
autolog
hsct
recipi
revaccin
clinic
relev
decreas
antibodi
vaccineprevent
diseas
among
hsct
recipi
immedi
appar
limit
number
case
vaccin
prevent
diseas
report
among
us
recipi
howev
vaccineprevent
diseas
still
pose
risk
us
popul
addit
evid
exist
certain
vaccineprevent
diseas
eg
encapsul
organ
pose
increas
risk
hsct
recipi
therefor
hsct
recipi
routin
revaccin
hsct
experi
immun
vaccineprevent
diseas
other
tabl
hsct
center
personnel
develop
vaccin
schedul
hsct
recipi
one
studi
determin
hsct
center
personnel
use
differ
vaccin
schedul
per
vaccin
consequ
studi
author
request
nation
guidelin
dose
time
vaccin
hsct
elimin
confus
among
hsct
center
personnel
regard
vaccin
patient
address
need
interim
vaccin
schedul
hsct
recipi
draft
collabor
partner
organ
includ
cdc
advisori
committe
immun
practic
purpos
vaccin
schedul
guidelin
provid
guidanc
hsct
center
tabl
although
limit
data
found
regard
safeti
immunogen
eg
serolog
studi
antibodi
titer
vaccin
among
hsct
recipi
data
found
regard
vaccin
efficaci
among
hsct
recipi
eg
determin
whether
vaccin
hsct
recipi
decreas
attack
rate
diseas
compar
unvaccin
hsct
recipi
certain
hsct
recipi
faster
immun
system
recoveri
hsct
other
research
propos
differ
vaccin
schedul
recommend
recipi
differ
type
hsct
howev
date
data
limit
therefor
vaccin
schedul
recommend
hsct
recipi
eg
allogen
autolog
bone
marrow
peripher
ucb
graft
addit
data
publish
tabl
vaccin
recommend
use
among
hsct
recipi
evid
exist
safeti
immunogen
recipi
vaccin
famili
broviac
doll
use
demonstr
medic
procedur
eg
insert
cathet
children
lessen
fear
member
household
contact
hcw
also
recommend
minim
exposur
vaccineprevent
diseas
among
hsct
recipi
tabl
allogen
hsct
life
recipi
might
depend
time
select
accept
hlamatch
donor
limit
number
hlamatch
donor
might
identifi
henc
transplant
physician
often
accept
higher
risk
transmiss
infecti
agent
hsct
would
permit
routin
blood
transfus
section
provid
strategi
hsct
physician
minim
transmiss
infecti
diseas
whenev
possibl
donor
recipi
whether
select
donor
risk
infecti
diseas
transmiss
hsct
determin
casebycas
basi
aiii
final
respons
hsct
physician
aiii
possibl
donor
risk
known
infect
bloodborn
pathogen
patient
like
succumb
rapidli
diseas
hsct
receiv
physician
must
care
weigh
risk
benefit
use
potenti
infect
donor
cell
person
deni
potenti
lifesav
hsct
procedur
sole
basi
risk
infecti
diseas
howev
hsct
physician
avoid
transplant
infect
infecti
donor
hematopoiet
stem
cell
product
unless
stem
cell
product
obtain
risk
death
undergo
transplant
deem
greater
risk
morbid
death
infect
could
potenti
transmit
dii
product
select
use
done
casebycas
basi
follow
note
recipi
chart
knowledg
author
recipi
hsct
physician
regard
potenti
transmiss
infecti
agent
hsct
advanc
inform
consent
recipi
recipi
legal
guardian
acknowledg
possibl
transmiss
infecti
agent
transplant
aiii
subsequ
hsct
physician
includ
infecti
agent
differenti
diagnosi
ill
hsct
recipi
experi
infect
transmit
diagnos
earli
treat
preemptiv
possibl
infecti
product
except
cmv
seroposit
evid
infecti
label
biohazard
untest
biohazard
applic
tissu
intend
autolog
use
label
autolog
use
use
patient
name
prospect
hsct
donor
evalu
physic
histori
examin
determin
gener
state
health
whether
pose
risk
transmit
infecti
diseas
recipi
detect
transmiss
infect
hsct
donor
collect
site
personnel
follow
uptod
publish
guidelin
standard
donor
screen
eg
medic
histori
physic
exam
serolog
test
aiii
initi
donor
screen
physic
exam
perform
week
plan
donat
biii
donor
serolog
test
done
day
donat
detect
potenti
transmiss
infect
bii
addit
research
recommend
donor
retest
day
collect
test
done
day
donat
donor
screen
repeat
ensur
new
risk
behavior
occur
interv
origin
screen
time
donat
biii
practic
critic
new
behavior
risk
factor
occur
potenti
donor
might
need
defer
screen
test
done
allogen
syngen
donor
aiii
screen
test
autolog
donor
recommend
ensur
safeti
laboratori
personnel
prevent
cross
contamin
biii
autolog
donor
test
autolog
unit
special
label
handl
potenti
infect
biii
donor
screen
unit
state
fdalicens
approv
test
use
accord
manufactur
instruct
aiii
donor
sampl
test
laboratori
certifi
clinic
laboratori
improv
amend
aiii
hsct
donor
good
gener
health
biii
acut
chronic
ill
prospect
donor
investig
determin
etiolog
gener
person
ill
hsct
donor
diii
flulik
ill
prospect
donor
time
evalu
time
evalu
donat
prompt
evalu
serolog
test
infect
might
pose
risk
recipi
eg
ebv
cmv
gondii
biii
person
posit
serum
ebvvir
capsid
antigen
igm
neg
serum
ebvvir
capsid
antigen
igg
serv
donor
allogen
tcelldeplet
hsct
particularli
unrel
mismatch
transplant
serum
ebvvir
capsid
antigen
igg
becom
posit
diii
person
acut
toxoplasmosi
donat
acut
ill
resolv
dii
howev
physician
awar
person
asymptomat
seroposit
gondii
might
transmit
infect
hsct
prospect
donor
symptom
activ
tb
evalu
diseas
biii
prospect
donor
activ
tb
donat
eiii
tb
wellcontrol
eg
longer
contagi
determin
donor
primari
physician
appropri
medic
therapi
howev
known
risk
exist
transplant
marrow
untreat
tuberculinposit
donor
evid
activ
diseas
screen
potenti
donor
tb
mantoux
skin
test
diii
necessari
prospect
hsct
donor
resid
travel
area
endem
rickettsia
tickborn
pathogen
suspect
acut
tickborn
infect
temporarili
defer
donor
infect
pathogen
exclud
diii
relev
pathogen
includ
rickettsia
rickettsii
babesia
microti
babesia
speci
coxiella
burnetii
colorado
tick
fever
viru
etiolog
agent
rocki
mountain
spot
fever
babesiosi
q
fever
colorado
tick
fever
respect
pathogen
report
transmit
blood
transfus
research
recommend
deferr
past
histori
q
fever
babesiosi
infect
chronic
babesiosi
parasit
might
persist
despit
appropri
therapi
ciii
addit
research
recommend
defer
person
acut
human
ehrlichiosi
eg
human
activ
human
granulocyt
ehrlichiosi
human
monocyt
ehrlichiosi
well
infect
ehrlichia
ewingii
hsct
donat
ciii
medic
histori
prospect
hsct
donor
includ
follow
histori
vaccin
week
donat
aii
potenti
donor
unsur
vaccin
receiv
record
review
hsct
donat
defer
week
donor
receiv
liveattenu
vaccin
eg
rubeola
measl
mump
rubella
german
measl
oral
polio
varicella
yellow
fever
oral
typhoid
vaccin
eiii
deferr
avoid
possibl
infus
live
infecti
agent
hsct
recipi
hsct
donat
need
defer
person
recent
receiv
toxoid
kill
ie
inactiv
recombin
viral
bacteri
rickettsi
vaccin
long
donor
asymptomat
afebril
biii
vaccin
includ
tetanu
toxoid
diphtheria
toxoid
hepat
b
cholera
influenza
ie
kill
intramuscular
vaccin
meningococc
paratyphoid
pertussi
plagu
polio
ie
inactiv
polio
vaccin
rabi
typhoid
ie
inactiv
intramuscular
vaccin
typhu
vaccin
travel
histori
biii
determin
whether
donor
ever
resid
travel
countri
endem
diseas
might
transmit
hsct
eg
malaria
perman
resid
nonendem
countri
travel
area
cdc
regard
endem
malaria
accept
hsct
donor
year
elaps
sinc
donor
departur
endem
area
donor
free
malaria
symptom
regardless
whether
receiv
antimalari
chemoprophylaxi
case
ofhscttransmit
malaria
report
person
malaria
receiv
appropri
treatment
defer
hsct
donat
year
becom
asymptomat
immigr
refuge
citizen
resid
year
endem
countri
accept
hsct
donor
year
elaps
sinc
depart
malari
area
free
malaria
symptom
histori
chaga
diseas
leishmaniasi
person
activ
chaga
diseas
leishmaniasi
serv
hsct
donor
diii
diseas
transmit
transfus
research
also
recommend
deferr
hsct
donat
past
histori
exist
either
diseas
parasit
persist
despit
therapi
ciii
histori
deferr
plasma
blood
donat
reason
deferr
whether
base
report
infecti
diseas
behavior
risk
factor
investig
biii
histori
viral
hepat
person
histori
viral
hepat
eleventh
birthday
exclud
hsct
donat
biii
histori
blood
product
transfus
solid
organ
transplant
transplant
tissu
within
last
month
biii
person
exclud
hsct
donat
diii
xenotranspl
product
recipi
close
contact
indefinit
defer
donat
blood
product
includ
hematopoiet
stem
cell
whole
blood
blood
compon
includ
plasma
leukocyt
tissu
aiii
close
contact
defer
donat
includ
person
engag
repeatedli
activ
could
result
intim
exchang
bodi
fluid
xenotransplant
product
recipi
close
contact
could
includ
sexual
partner
household
member
share
razor
toothbrush
hcw
laboratori
personnel
repeat
percutan
mucos
direct
exposur
histori
risk
factor
classic
creutzfeldtjakob
diseas
cjd
includ
blood
rel
creutzfeldtjakob
diseas
receipt
human
pituitaryderiv
growth
hormon
receipt
corneal
dura
mater
graft
biii
potenti
hsct
donor
also
screen
new
variant
creutzfeldtjakob
diseas
nvcjd
risk
factor
includ
histori
cumul
travel
resid
unit
kingdom
month
receipt
inject
bovin
insulin
sinc
unless
product
manufactur
sinc
cattl
unit
kingdom
biii
clinic
latenc
period
iatrogen
classic
cjd
year
transmiss
classic
cjd
blood
product
highli
unlik
although
classic
nvcjd
ever
report
among
hsct
recipi
person
histori
classic
nvcjd
risk
factor
exclud
donat
unrel
hsct
diii
choic
exist
two
otherwis
equal
suitabl
donor
risk
transmit
classic
nvcjd
hsct
donor
recipi
unknown
research
believ
person
nvcjd
risk
factor
could
higher
risk
transmit
nvcjd
hsct
recipi
person
classic
cjd
risk
factor
past
medic
histori
indic
donor
clinic
evid
high
risk
acquir
bloodborn
infect
eg
person
report
past
medic
histori
exclud
donat
diii
follow
serolog
test
perform
prospect
donor
antigen
antihtlvi
ii
hepat
b
surfac
antigen
total
antihepat
b
core
antigen
antihepat
c
anticmv
serolog
test
syphili
aiii
potenti
donor
repeatedli
reactiv
screen
test
antigen
antihtlvi
ii
antihepat
c
hepat
b
surfac
antigen
antihepat
b
core
antigen
exclud
hsct
donor
eii
person
refus
infecti
diseas
test
also
exclud
hsct
donor
eiii
investig
nucleic
acid
test
detect
hepat
c
viru
rna
hiv
rna
current
use
unit
state
screen
blood
donor
could
use
screen
hsct
donor
nucleic
acid
test
approv
fda
test
incorpor
routin
screen
regimen
hsct
donor
nucleic
acid
test
done
hiv
hepat
c
investig
posit
result
exclud
potenti
donor
infecti
diseas
test
result
report
hsct
physician
candid
condit
regimen
begin
aiii
bone
marrow
collect
use
steril
techniqu
medic
accept
set
accord
standard
oper
procedur
aiii
hsct
transplant
center
personnel
keep
accur
record
hsct
receiv
disposit
sampl
obtain
track
record
must
separ
patient
medic
record
eg
log
book
inform
easili
obtain
record
inform
includ
donor
identif
number
name
procur
distribut
center
suppli
hsct
recipientidentifi
inform
name
recipi
physician
date
receipt
hsct
center
b
either
transplant
recipi
distribut
aiii
center
donat
transplant
collect
hematopoiet
stem
cell
keep
record
donor
screen
test
hsct
harvest
process
test
cryopreserv
storag
infus
dispos
aliquot
donat
hematopoiet
progenitor
cell
year
date
implant
transplant
infus
transfer
product
aiii
howev
date
known
record
retain
year
product
distribut
disposit
expir
whichev
latest
children
age
month
born
mother
risk
hiv
infect
breastf
past
month
whose
hiv
antibodi
test
physic
examin
medic
record
indic
evid
hiv
infect
accept
donor
biii
children
age
month
born
mother
risk
hiv
infect
breastf
hivinfect
woman
past
month
accept
donor
hiv
infect
exclud
accord
establish
criteria
biii
children
breastf
hivinfect
woman
past
month
exclud
stem
cell
donor
regardless
hiv
infect
statu
aiii
mother
possibl
father
pediatr
stemcel
donor
risk
perinat
transmiss
hiv
bloodborn
infect
interview
healthcar
profession
compet
elicit
inform
regard
risk
factor
possibl
bloodborn
infect
potenti
pediatr
donor
aiii
children
meet
adult
donor
exclus
criteria
becom
hsct
donor
eiii
personnel
donat
collect
transplant
center
cellprocess
laboratori
courier
servic
follow
current
standard
detect
prevent
extrins
bacteri
fungal
contamin
collect
stem
cell
unit
collect
site
process
transport
transplant
center
aiii
qualiti
improv
program
procedur
manual
collect
center
cellprocess
laboratori
transplant
program
includ
strategi
prevent
transplantassoci
infect
exampl
collect
center
use
asept
techniqu
collect
marrow
peripher
blood
ucb
hematopoiet
stem
cell
aiii
whenev
possibl
close
system
use
pool
hematopoiet
stem
cell
collect
procedur
biii
higher
rate
microbi
contamin
seen
marrow
harvest
versu
blood
stem
cell
collect
caus
use
open
collect
system
highest
risk
extran
microbi
contamin
hematopoiet
stem
cell
occur
extens
manipul
process
laboratori
potenti
sourc
includ
unprotect
hand
laboratori
equip
freezer
particularli
liquid
phase
liquid
nitrogen
freezer
therefor
stem
cell
process
perform
accord
current
standard
use
approv
manufactur
practic
aiii
hematopoiet
stem
cell
unit
thaw
water
bath
enclos
second
bag
ie
doublebag
techniqu
prevent
contamin
port
cap
unsteril
bath
water
biii
addit
water
bath
clean
routin
biii
certain
research
propos
bath
contain
steril
water
ciii
research
also
report
steril
liquid
nitrogen
freezer
initi
use
hematopoiet
stem
cell
storag
fungal
bacteri
cultur
neg
ciii
cellprocess
laboratori
personnel
implement
program
detect
extrins
bacteri
fungal
contamin
collect
stem
cell
unit
ideal
transplant
aiii
although
repeat
cultur
costli
donat
hematopoiet
stem
cell
cultur
aerob
bacteria
fungi
time
initi
process
freez
biii
research
also
propos
ad
anaerob
bacteri
cultur
cultur
twice
end
process
thaw
use
ciii
bacteri
cultur
result
posit
antibioticsuscept
test
perform
biii
result
cultur
antibioticsuscept
test
provid
transplant
physician
releas
cryopreserv
marrow
blood
stem
cell
unit
soon
feasibl
transplant
infus
complet
cultur
incub
biii
collect
center
cellprocess
laboratori
transplant
program
personnel
maintain
activ
surveil
infect
among
person
receiv
hematopoiet
stem
cell
facil
collect
data
regard
number
infect
hsct
might
caus
exogen
contamin
donor
stem
cell
biii
type
infect
report
nation
standard
exist
utero
fetal
hsct
overal
risk
transmit
infect
fetu
hsct
determin
howev
addit
precaut
appropri
adult
recipi
physician
perform
utero
fetal
hsct
advis
evalu
potenti
donor
evid
activ
infecti
diseas
could
caus
seriou
congenit
infect
eg
rubella
varicella
cmv
syphili
gondii
fetu
ciii
routin
vaccin
recommend
person
increas
risk
hepat
advers
consequ
eg
person
chronic
liver
diseas
person
travel
hepat
aendem
countri
children
age
month
live
area
consist
elev
hepat
incid
household
contact
vaccin
strongli
recommend
influenza
season
ie
octobermay
begin
season
transplant
continu
month
hsct
household
contact
immunocompromis
hsct
recipi
vaccin
annual
long
condit
persist
hcw
home
caregiv
annual
vaccin
strongli
recommend
influenza
season
vaccin
routin
recommend
adult
administ
polio
vaccin
indic
accord
publish
advisori
committe
immun
practic
guidelin
polio
vaccin
administ
inactiv
polio
vaccin
use
vaccin
recommend
person
age
month
pregnant
immunocompromis
contraind
intussuscept
report
among
infant
first
week
rotaviru
vaccin
substanti
increas
frequenc
vaccin
administ
suscept
hcw
household
contact
famili
member
age
month
pregnant
immunocompromis
varicella
vaccin
administ
person
age
year
dose
requir
administ
week
apart
postexposur
vaccin
administ
without
tetanu
immunoglobulin
indic
tetanu
exposur
occur
anytim
hsct
ideal
administ
hsct
recipi
hour
close
contact
person
varicella
shingl
hsct
recipi
month
hsct
b
month
hsct
still
immunocompromis
administr
extend
varicella
incub
period
day
day
hsct
recipi
experi
varicellazost
viruslik
rash
contact
exposur
person
varicella
herp
zoster
antivir
drug
therapi
administ
day
lesion
crust
administ
hepat
asuscept
hsct
recipi
anticip
hepat
exposur
eg
travel
endem
area
postexposur
prophylaxi
indic
also
administ
measl
exposur
among
hsct
recipi
vaccin
measl
hsct
administ
hsct
recipi
sever
hypogammaglobulinemia
immunoglobulin
g
mg
dl
day
hsct
prevent
bacteri
infect
appendix
note
rsv
intraven
immunoglobulin
contraind
among
patient
immunoglobulin
defici
might
allerg
reaction
anaphylaxi
receiv
blood
product
contain
immunoglobulin
diii
rsv
monoclon
antibodi
investig
use
among
hsct
recipi
treatment
ribavirin
prophylaxi
research
also
propos
check
serum
immunoglobulin
g
level
everi
week
patient
receiv
intraven
immunoglobulin
replac
therapi
